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Deep sequencing and functional analyses identify a role of  
Fusobacterium species in colorectal tumorigenesis 
 
 
Abstract 
 
 
 The tumor microenvironment is a complex community consisting of neoplastic cells, 
surrounding stromal cells, a broad array of immune cells, and a microbiota. By sheer numbers, 
the microbiota has its greatest manifestation in colorectal cancer (CRC) because the colon 
contains up to 100 trillion bacteria, outnumbering human cells by a factor of 10 and encoding a 
gene-content that is 100-fold larger than that of the human genome. Indeed, previous studies 
using germ-free mice in a variety of genetic backgrounds have demonstrated that the microbiota 
can impact colorectal tumorigenesis. In addition, specific strains of enterotoxigenic bacteria have 
been shown to promote colitis-associated cancer in mice. Here, we explore the composition of 
the tissue-associated microbiota in human CRC and evaluate the role of tumor-enriched microbes 
in potentiating colorectal tumorigenesis in mice. 
 Advances in DNA sequencing technology have fueled a renaissance in the microbiome 
field. Deep sequencing metagenomics enables rapid, culture-independent characterization of a 
microbial community. We present PathSeq, a highly scalable software tool that performs 
computational subtraction on high-throughput sequencing data to identify nonhuman nucleic 
acids. PathSeq makes it possible to analyze sequence datasets as large as human whole-genomes 
for the purpose of metagenomics and also to discover previously unsequenced microorganisms. 
We used PathSeq to characterize the composition of the microbiota in human CRC using whole-
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genome sequencing on nine tumor/normal pairs and 16S rDNA sequencing on an additional 95 
pairs. The genus Fusobacterium was highly enriched in tumors, while the Bacteroidetes and 
Firmicutes phyla were depleted. 
We show that in the ApcMin/+ mouse model of intestinal tumorigenesis, Fusobacterium 
nucleatum increases tumor multiplicity, selectively recruits tumor-infiltrating myeloid cells, and 
is associated with a pro-inflammatory expression signature that is shared with human 
fusobacteria-positive colorectal carcinomas. We find that Fusobacterium spp. are enriched in 
human colonic adenomas relative to surrounding tissues and fusobacterial abundance is 
increased in stool samples from patients with colorectal adenomas and carcinomas, compared to 
healthy subjects. Collectively, these data support that fusobacteria may be involved in early 
stages of intestinal tumorigenesis and, through recruitment of tumor-infiltrating immune cells, 
may generate a pro-inflammatory tissue microenvironment conducive to colorectal neoplasia 
progression. 
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Portions of this Introduction appear in the following publication: 
Kostic, A.D., Howitt, M.R., Garrett, W.S. Exploring host-microbiota interactions in animal models and humans. 
Genes & Development (in press). 
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Overview 
At the most fundamental level, a tumor is composed of a group of neoplastic cells 
harboring aberrant genomes that endow it with the ability to proliferate beyond normal means. 
Hanahan and Weinberg famously described the six hallmarks of cancer that most, if not all, 
tumors must acquire: self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis [1]. The focus of cancer research in the decades leading up to this 
seminal review had been on the cancer cell. But the tumor microenvironment, composed of not 
only the neoplastic cells themselves but also the surrounding stromal cells and a vast array of 
immune cells, may be just as important to the tumorigenic process as the cancer cell itself [2]. 
Malignant cells do not act alone in driving cancer, but rather they influence their surrounding 
cells to participate in the growth of the tumor. The past decade has seen tremendous advances in 
our understanding of the contribution of the microenvironment to tumorigenesis, and therefore it 
may not be surprising that the hallmarks of cancer have been recently updated to include four 
additional members that emphasize the role of the microenvironment: tumor-promoting 
inflammation, avoidance of immune destruction, deregulating cellular energetics, and genome 
instability and mutation [3]. 
The past decade has also seen a reimagining of the extent of our physiological interaction 
with our resident microbiota. Recent research has revealed roles for the microbiome in host 
physiology ranging from angiogenesis [4,5] and skeletal biology [6,7] to lipid metabolism [8,9] 
and even behavior [10-13]. Likewise, there is an increasing interest in the impact of the 
microbiota on cancer [14]. The lumen of the human distal gut is one of the most densely 
populated ecosystems on our planet, and we also harbor several distinct microbiomes on the 
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other surfaces of our body such as the respiratory and urogenital tracts and the skin. The number 
of bacterial cells on our body outnumber our own cells by a factor of ten, and from a functional 
standpoint, the number of genes encoded in our microbiome outnumbers the genes in our 
genome by a factor of 100. Therefore, the tumor microenvironment, in addition to containing 
neoplastic cells, stromal cells, and immune cells, should also be considered in the context of an 
additional component: the tumor microbiota. 
In this Introduction I explore the roles of the microbiota and microbiota-associated 
inflammation in cancer. I use the colon as a model ecosystem for these interactions, although the 
microbiota and inflammation can have influences on cancer types beyond intestinal cancers. 
 
The Human Gastrointestinal Microbiota 
Overview 
 The meta’omics revolution in both deep sequencing and big data analytics is fostering an 
explosion of interest in how the gut microbiome impacts physiology and propensity to disease. 
Also driving interest in this field is the relatively recent discovery of the causal role of 
Helicobacter pylori in duodenal ulcers and gastric cancers [15,16], the role of the gut microbiota 
in inflammatory bowel disease [17], a new understanding of the impact of antibiotic use on the 
microbiota and the emergence of opportunistic pathogens [18,19], and the therapeutic use of 
fecal transplantation. Although the first successful application of fecal transplantation to 
Clostridium difficile-associated disease was first reported more than 50 years ago, the astounding 
clinical efficacy of this approach has only recently been demonstrated in a controlled trial [20]. 
The microbiota is necessary for the maintenance of physiologic homeostasis, but in the 
context of specific microbial and/or host phenotypes, the microbiota can contribute to disease 
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pathogenesis. For instance, the type VI secretion system (T6SS) of Helicobacter hepaticus 
directs an anti-inflammatory gene expression profile on intestinal epithelial cells (IECs) to create 
a tolerogenic immune environment, but H. hepaticus T6SS mutants disrupt this balance and 
promote colitis by driving a T helper type 17 T cell (Th17) response [21]. H. hepaticus is an 
example of what has been termed a pathobiont, a symbiotic microbe that is capable of promoting 
pathology only when specific host, environmental, or microbial factors are altered [22,23]. 
Similarly, Helicobacter pylori is a human pathobiont that is a resident of the stomach in 50% of 
the population globally [24] and may be protective against asthma and other allergic disease 
[18,25,26], but under specific conditions which have yet to be completely defined, H. pylori 
causes gastric cancer [16]. Host genetics also play a role in making a pathobiont pathogenic. For 
example, germ-free Il10-/- mice do not show any signs of intestinal inflammation, but when they 
are colonized by commensal strains of E. coli and Enterococcus faecalis that do not cause any 
disease in wild-type mice, these bacteria drive severe colitis in the IL-10-deficient mouse [27]. 
The emergence of pathobionts can also be influenced by diet [28] and by the use of antibiotics 
[29]. 
The Intestinal Ecosystem: The Flora 
 There is significant variability in the density and complexity of the microbiota throughout 
the body. Within the gastrointestinal tract, we harbor 108-10 colony-forming units (CFU) of 
bacteria per gram (g) of saliva, 103 CFU/g of gastric juice, 102-4 CFU/g of contents in the 
duodenum and jejunum of the small intestine, 1010 CFU/g in the small intestinal ileum, and 1010-
14 CFU/g of colonic content [14]. Interestingly, the higher microbial density in the colon relative 
to the small intestine correlates with a greater than 12-fold risk of cancer in the colon [30]. The 
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human gastrointestinal tract is home to more than 100 trillion bacteria, and the microbiome 
contains as many as 150 times the number of genes in the human genome [31,32].  
 The human intestinal microbiota is comprised predominantly of two phyla, the Firmicutes 
and Bacteroidetes, with a smaller representation of the Proteobacteria and Actinobacteria, and a 
rare representation of the Fusobacteria, Verrucomicrobia, and Cyanobacteria [30,33,34]. The 
mouse serves as an excellent model for microbiota studies because its gut microbiota bears 
striking similarities to ours [35]. The intestinal microbiota is dominated by strict anaerobes, most 
notably the genera of Bacteroides, Eubacterium, Bifidobacterium, Peptostreptococcus, and 
Atopobium, whereas facultative anaerobes are present at 1,000-fold lower levels [14]. 
Approximately 500 to 1,000 different species comprise the normal colonic microbiota [36].  
 Comprehensive characterizations of the “healthy” human adult microbiota have been 
carried out by the European and Chinese-led Metagenomics of the Human Intestinal Tract 
(MetaHIT) Consortium and the NIH-sponsored Human Microbiome Project (HMP). MetaHIT 
focused on shotgun metagenomic sequencing of fecal samples from 146 European individuals, 
uncovering the presence of a minimal gut genome and metagenome, based on taxonomy and 
gene functionality [37]. MetaHIT reported that individuals, regardless of gender, race, or 
geography, can be grouped into one of three enterotypes characterized by variation in the level of 
the Bacteroides, Prevotella, and Ruminococcus genera [38], however recent studies have favored 
a continuum or gradient of species rather than discrete enterotypes [39-41]. The HMP has, in a 
series of 16 articles published in parallel (www.plos-collections.org/hmp), produced the largest 
dataset to-date of the diversity of the human microbiome across body sites on a large number of 
healthy adults. The HMP carried out both 16S rRNA gene sequencing and metagenomic 
sequencing on 15 (for males) or 18 (for females) body sites on each of 242 healthy adults in the 
	   6 
United States sampled on three separate visits [42]. The gut and tooth habitats were found to 
harbor the greatest between-subject microbial diversity but also the lowest between-visit 
variability, whereas the skin had lower between-subject diversity but much higher between-visit 
variability [43]. These studies suggest that the composition of the microbiota varies substantially 
across individuals, though it is temporally stable within a single person, and the functionality of 
the microbiota at the gene-level is highly conserved across individuals [43]. 
The Intestinal Ecosystem: The Host 
 Though host-microbiota interactions are bidirectional, direct contact with the epithelium 
is limited by a thick mucus layer and secreted factors. The mucus layer is principally composed 
of mucin, a high molecular weight glycosylated protein, and also consists of trefoil peptides, 
antimicrobial peptides, and secretory IgA [44]. The colon has a 150µm inner mucus layer that is 
firmly adherent to the epithelium and a variable-thickness outer layer that is loose and non-
attached, whereas the small intestine has a single-layer incomplete barrier [45,46]. α-defensins, 
small antibacterial peptides secreted by Paneth cells of the small intestine, are required for the 
maintenance of the composition of the luminal microbiota [47]. By contrast, RegIIIγ is a secreted 
antimicrobial lectin that does not affect the luminal microbiota, rather it is limited to the mucus 
layer and restricts the access of Gram-positive bacteria to the epithelium [48,49]. 
 
Colorectal Cancer 
 Gastrointestinal cancers account for 25% of all cancer incidences and for 9% of cancer 
deaths globally [36], and there are nearly 1 million new cases of colorectal cancer (CRC) 
worldwide each year (http://www.who.int/en). Familial CRC accounts for 15-20% of CRC cases 
[50], which are classified as familial adenomatous polyposis (FAP), MYH-associated polyposis, 
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hereditary nonpolyposis CRC, hamartomatous polyposis syndromes, or hyperplastic polyposis 
syndrome [51]. The genes responsible for the majority of these disorders have been uncovered: 
MHL1, MSH2, MSH6, PMS2, APC, MYH, STK11, SMAD4, BMPR1A, and PTEN [51]. One of 
the most widely used mouse models of CRC, the ApcMin/+ mouse, bears a heterozygous mutation 
in the tumor suppressor gene APC [52,53], as do patients with FAP [54-56]. The ApcMin/+ mouse 
will develop tens to hundreds of tumors in the small and large bowel [52], whereas FAP patients 
can develop thousands of adenomas but they are limited to the large bowel [57]. The 
identification of the germline mutations responsible for familial CRC has been instrumental in 
understanding the molecular pathways that underlie sporadic (i.e. non-familial) CRC. 
 CRC tumorigenesis proceeds through a series of genetic alterations, as first proposed by 
Fearon and Vogelstein [58]. The Wnt—β-catenin signaling pathway is essential for intestinal 
epithelial cell renewal, and mutations that lead to Wnt—β-catenin activation occur early in the 
course of tumorigenesis in greater than 90% of sporadic CRC cases; these mutations most 
commonly occur in APC and also GSK3B, which encodes a kinase that controls APC and β-
catenin stability [59,60]. The hyperpoliferative epithelium will then accumulate additional 
mutations, most commonly in KRAS and TP53, as it increases in size, dysplasia, and villous 
content to form a malignant tumor [58]. Recent large scale cancer genome sequencing efforts 
have confirmed that APC, TP53, and KRAS are the most commonly mutated genes in non-
hypermutated CRC tumors, but mutations in PIK3CA, SMAD4, and the F-box protein FBXW7 
are also frequently observed [61], as well as a recently-discovered recurrent VTI1A-TCF7L2 
fusion [62]. 
 Colitis-associated cancer (CAC) is a form of colon cancer that is preceded by clinically 
detectable inflammatory bowel disease (IBD). IBD is classified into either ulcerative colitis 
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(UC), characterized by a non-transmural mucosal inflammation that is limited to the colon, and 
Crohn’s disease (CD), which is a transmural inflammation of the mucosa that can affect the 
entire gastrointestinal tract [63,64]. Patients with CD have an 8% increased cumulative risk of 
CAC after 30 years of active CD, and for UC patients it is 18-20% [65]. The risk of developing 
CRC is 10-fold higher for individuals with IBD compared to the healthy population [30], 
however less than 2% of all CRC cases have a history of IBD [66]. Interestingly, wild-type (WT) 
mice can reproducibly develop CAC by administering the detergent dextran sulfate sodium 
(DSS) in the drinking water along with a single injection of the carcinogen azoxymethane 
(AOM) [67]. In contrast to sporadic CRC, mouse models of CAC develop mutations affecting 
Wnt—β-catenin signaling relatively late in the tumorigenic process, and develop early mutations 
in Trp53 and Kras [60,68]. 
 
The Role of Inflammation in Colorectal Cancer 
 Inflammation is a hallmark of cancer [3]. Chronic inflammation can drive sustained 
innate immune cell recruitment, tumor growth, and metastasis, and directly promotes malignant 
cell transformation by inducing chromosomal and microsatellite instability, CpG island 
methylation, epigenetic alteration, and post-translational modifications [44]. Therefore, 
inflammation can contribute to all three stages of tumorigenesis: initiation, promotion, and 
progression [69].  
 Inflammation contributes to tumor initiation by virtue of its ability to cause mutations. 
Indeed, mucosal inflammation elicits systemic DNA damage that can contribute to tumoral 
genetic instability [70,71]. For example, mice deficient in ATM, a kinase involved in DNA 
double-strand break recognition and repair, show not only elevated DNA damage, but persistent 
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immune activation and increased sensitivity to DSS-induced colitis [72]. Another integral 
component of the DNA damage repair machinery, p53, is one of the most commonly mutated 
genes in CAC, but is also found to be mutated in colitic tissue without signs of dysplasia [73]. 
Inflammatory cells, particularly activated neutrophils and macrophages, produce significant 
amounts of reactive oxygen species and reactive nitrogen species that cause oxidative damage 
and can directly lead to oncogenic mutations in inflamed tissue [60]. 
 Once a tumor has been initiated, there are numerous mechanisms by which inflammation 
can contribute to tumor promotion (i.e. proliferation) and progression (i.e. malignant 
transformation, invasion, and metastasis).  
The Role of Inflammatory Responses to the Microbiota in Cancer 
 Pattern recognition receptors (PRRs) are the fingers of the immune surveillance system. 
They are an elegant set of receptors that can identify microbial ligands such as cell wall 
components or nucleic acids and are expressed on intestinal epithelial cells and mucosal immune 
cells. PRRs include Toll-like receptors (TLRs), Nucleotide-binding domain leucine-rich repeat 
proteins or NOD-like receptors (NLRs), and C-type lectin receptors (CLRs) among others [74-
76]. TLRs and NLRs recognize the symbiotic microbiota, induce host defense responses against 
pathogens, and control adaptive immune responses. TLRs are transmembrane proteins containing 
leucine-rich repeats that play a crucial role in the innate immune response by sensing microbe-
associated molecular patterns on bacteria, viruses, or parasites in the extracellular environment 
(TLRs 1, 2, 4-6, 11) or in endolysosomes (TLRs 3, 7-9, 10).  
MyD88 
 MyD88 is an adaptor protein common to IL-1 and IL-18 signaling and to the TLRs (with 
the exception of TLR3). Thus, loss of MyD88 may be expected to impact a wide range of innate 
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immune sensing of the microbiota. The absence of MyD88 in the non-obese diabetic mouse 
strain led to an altered microbiota composition with enriched abundance of Lactobacillaceae, 
Rikenellaceae, and Porphyromonadaceae [77]. In another recent study, loss of MyD88 was 
examined from both a microbial ecology and host transcriptome perspective along the length of 
the small intestine and colon [78]. The small intestinal microbiota of MyD88-deficient mice was 
notable for an enrichment of segmented filamentous bacteria (SFB) and greater interindividual 
variation. Recently, SFB have garnered increased attention, as they promote a population of T 
cells [79], called T helper 17 cells, which function in immunity against extracellular bacteria and 
fungi. Targeted intestinal epithelial deletion of MyD88 using Villin-Cre X MyD88-Flox mice has 
revealed that such mice have reduced levels of the polymeric immunoglobulin receptor mucin-2 
and antibacterial peptides [80]. MyD88 also regulates of the expression of RegIIIγ, the 
antibacterial lectin that restricts the localization of bacteria and ensures its proper segregation 
from the inner mucus layer of the intestinal mucosa [48]. MyD88 has been demonstrated to have 
roles in promoting cancer as well. MyD88-/- mice formed fewer skin papillomas when exposed to 
the carcinogens 7,12-dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol 13-
acetate (TPA), fewer fibrosarcomas when exposed to 3′-methylcholanthrene (MCA) [81], and 
fewer hepatic tumors in the diethylnitrosamine (DEN)-induced model of liver cancer [82] 
compared to WT mice. MyD88-deficient mice develop less inflammation and decreased colonic 
tumorigenesis compared to WT when treated with oxazalone-AOM [83] or DSS-AOM [84]. 
MyD88 is also instrumental in driving intestinal tumorigenesis in ApcMin/+ mice. ApcMin/+X 
MyD88-/- mice have significantly reduced small intestinal and colonic tumors relative to ApcMin/+ 
mice [85] because MyD88 signaling post-transcriptionally stabilizes the c-myc protein through 
activation of the kinase ERK, which induces the multiple intestinal neoplasia phenotype [86]. 
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TLRs 
 There have been several studies on the impact of the TLRs upstream of MyD88. 
Investigations of TLR5-deficient mice have revealed phenotypes resulting in metabolic 
syndrome [87]and colitis [88], with coincident alterations in the microbiota and transient 
elevations in the Proteobacteria and, in particular, enterobacterial species in colitic Tlr5 knockout 
mice [87,89]. While there have been other observations supporting that alterations in TLR 
signaling impact the microbiota (e.g., that there is an altered colonic mucosal microbiota in Tlr2-
/- mice) [90], other studies have challenged the magnitude of the impact of TLR signaling 
perturbations on the gut microbiome. A denaturing gradient gel electrophoresis and fluorescence 
in situ hybridization (FISH)-based investigation [91] and a more recent study using deep 16S 
rRNA gene surveys both call into question whether TLRs or MyD88 alter the gut microbiota in a 
genotype-dependent fashion [92]. Ubeda et al. (2012) generated MyD88-, TLR2-, TLR4-, TLR6-
, and TLR9-deficient mouse lines from heterozygote X heterozygote breeding strategies. 
Interestingly, they did not detect statistically significant differences in community composition 
or diversity in cecal luminal, ileal luminal, or ileal microbial communities in these mice 
compared with their littermate controls. They also did not detect statistically significant 
differences in microbial community response after an antibiotic (vancomycin) perturbation. 
However, differences were observed between WT and TLR-mutant colonies that had been 
maintained as separate lines from homozygous X homozygous crosses for many years. These 
results raise awareness about the importance of considering lineage or legacy effects in 
microbiome studies, and it should be noted that these effects were considered in several of the 
cited studies [48]. Like its roles in shaping the microbiota, the impact of TLRs on intestinal 
tumorigenesis is also currently not well understood. Deletion of Tlr4, which is responsible for 
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detecting lipopolysaccharide of Gram-negative bacteria, protects DSS-AOM-treated mice from 
developing colon tumors [93,94], but deficiency of TLR2, which recognizes peptidoglycan and 
lipoteichoic acid among other molecules produced by bacteria and fungi, results in an increased 
intestinal tumor load [95]. 
NLRs and the Inflammasome 
 The other major class of PRRs are the NLRs. The NLRs are a central component of the 
inflammasome, which drives an innate immune response against intracellular pathogens [96,97]. 
The inflammasome is a multiprotein complex that is composed of several members of the NLR 
family, Procaspase-1, and the adaptor protein ASC [98]. Inflammasome activation results in 
Caspase-1 activation and subsequent Caspase-1 proteolytic activation of two proinflammatory 
cytokines: IL-1β and IL-18 [99]. Mutations in the NLR family member NOD2 increase the risk 
of Crohn’s disease. Nod2 expression in the intestine is dependent on the presence of a gut 
microbiota, and Nod2 knockout mice are more susceptible to colonization by intestinal mouse 
pathogens [100]. Mice deficient in Nod1 and Nod2 have altered gut microbiota composition as 
compared with their heterozygous littermates [101]. Nod1 is expressed ubiquitously in intestinal 
epithelial and immune cells, and recognizes the peptidoglycan of Gram-negative bacteria 
[102,103]. Nod1 has a protective role against colitis-associated cancer; DSS-AOM-treated Nod1-
/- mice develop more colonic tumors than DSS-AOM-treated WT mice, and ApcMin/+X Nod1-/- 
mice exhibit increased intestinal tumors than ApcMin/+ controls [104]. NLRP6 is a NLR family 
member that functions in inflammasome, type 1 interferon, and NF-κB signaling. NLRP6 
inflammasome-deficient mice have an altered gut microbiota notable for an expansion of 
Prevotellaceae and the TM7 phylum [105]. Although why this bacterial family expands remains 
unclear, this microbiota is functionally significant because co-housing and cross-fostering 
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experiments have revealed that the microbiota and the phenotype are transferable to WT mice, 
leading to increased colitis severity induced by DSS [105,106]. NLRP6 is a negative regulator of 
inflammatory signaling, and its loss activates MAP kinase and NF-κB signaling pathways 
downstream from TLRs and increases circulating monocyte numbers [107]. These cellular and 
signaling alterations may explain why NLRP6-deficient mice have an increased resistance to a 
number of pathogenic bacteria and an altered endogenous microbiota [107]. NLRP6 also has a 
role in suppressing inflammation-induced colon tumorigenesis, because Nlrp6-/- mice have 
increased colitis and colonic tumors when treated with DSS-AOM compared to WT controls 
[108,109]. Similar phenotypes are seen in mice deficient in the related NLR family members 
Nlrp3 [110,111] and Nlrp12 [112,113]. Caspases are cysteine proteases that play wide-ranging 
roles functioning in apoptosis to inflammation. Caspase-1 cleavage of IL-1β and IL-18 
contributes to regulating inflammatory tone in the gut and thus may modulate the microbiome. 
The gut microbiota of Capsase-1-, Capsase-3-, and Capsase-7-deficient mice were recently 
evaluated in comparison with WT mice using 16S rRNA gene fecal profiling, and significant 
differences were observed across several families, including Lachnospiraceae, 
Porphyromonodaceae, and Prevotellaceae [114]. In keeping with the pivotal role of caspases in 
inflammasome function and consequently suppression of tumorigenesis, both Caspase-1-
deficient [115] and Caspase-12-deficient [116] mice have increased susceptibility to developing 
colon tumors following treatment with DSS-AOM. 
 An intriguing insight that is gleaned from these studies is that, while both pathways are 
similarly involved in microbial detection and innate immune response, TLR/MyD88 signaling 
promotes the development of CRC, whereas NLR and inflammasome signaling appears to 
protect the host from CRC. This difference might be dictated by the motif that the PRR 
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recognizes or the location (i.e. extra- versus intracellular) of the PRR [30]. 
Defensins 
 TLRs and NLRs are of course not the only molecules involved in host response to the 
microbiota that affects tumorigenesis. Defensins are cationic proteins found in both the animal 
and plant kingdom that have broad antimicrobial activity against bacteria, fungi, and viruses, and 
the microbiota of mice with altered enteric defensin activity have been investigated. In mice and 
humans, defensins are principally produced by small intestinal Paneth cells and also by intestinal 
absorptive enterocytes [117]. Intestinal tissue and luminal samples from transgenic mice 
expressing one or two copies of the human α-defensin (DEFA5) and knockout mice deficient in 
the metalloprotease MMP7, which proteolytically activates α-defensin, were analyzed showed 
several significant differences in the gut microbiota from the phylum to the species level, 
including a strong reduction in the SFB [118]. Interestingly, α-defensin shows killing activity 
against Helicobacter pylori at low concentrations in vitro [119]. While it may seem intuitive that 
antimicrobial molecules, TLRs, and NLRs would impact the microbiome, the microbiome field 
is relatively young. Thus, there is a need to define the impact of such genes on the microbiota 
and clarify whether changes are stochastic or host genotype driven. 
NF-κB Activation and the IL-6—STAT3 Axis 
 Inflammatory processes lead to the production of cytokines and growth factors that 
prevent malignant cells from apoptosis [120,121]. Genetic ablation of components of the NF-κB 
pathway or factors in STAT3 activation in epithelial cells blocks the expression of anti-apoptotic 
genes including Bcl-xL and Bcl-2, resulting in increased levels of apoptosis and more severe 
colitis, but remarkably, decreased tumor load [122-124]. When NF-κB activity was specifically 
ablated in myeloid cells with the use of IKKβ floxed mice and the LysMcre conditional deleter, 
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both colon tumor size and multiplicity were significantly reduced [122]. NF-κB activation in 
myeloid cells controls the expression of multiple inflammatory and tumor-promoting cytokines, 
including TNF-α and IL-1β [125,126], which are capable of activating NF-κB in epithelial and 
malignant cells [60]. 
 NF-κB activation in myeloid cells also leads to the production of IL-6. IL-6 is a key 
cytokine in CAC; IL-6 enhances the proliferation of colonic carcinoma cells in vitro, is required 
for the survival of IECs and development of CAC in vivo, and interference with IL-6 signaling in 
the late stages of CAC results in the slowing of tumor growth [124,127,128]. IL-6 can influence 
the differentiation of Th17 cells (and IL-17 produced by Th17 cells in turn induce the IL-6—
STAT3 signaling pathway [129], forming a positive feedback loop), the suppression of 
regulatory T cells (Tregs), regulate the recruitment of many myeloid cell subtypes, among other 
functions that influence the immune response [130,131]. 
IL-6 production by myeloid cells in turn drives STAT3 activation in epithelial cells, 
which can then also result in the activation of the Ras—Erk and PI3K—Akt pathways [60]. 
STAT3 leads to the up-regulation of anti-apoptotic genes (Bcl-xL and Bcl-2), cell cycle 
regulators (Cyclin D1, c-myc), and angiogenic factors (bFGF, VEGF) [121,132]. Conversely, the 
epithelial inactivation of STAT3 reduces cell survival and proliferation, and results in decreased 
CAC tumor growth and multiplicity [123,124]. 
IL-23 
 IL-23 is a member of the IL-12 cytokine family. IL-23 expression is up-regulated in 
many cancers including CRC [133,134], and IL-23 receptor (IL-23R) blockade reduces intestinal 
inflammation and tumor growth in ApcMin/+ mice colonized with enterotoxigenic Bacteroides 
fragilis [135] (see Associations between Single Bacterial Species and Cancer). IL-23 may be a 
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key factor in driving intestinal tumorigenesis that results from epithelial barrier defects and 
infiltration of luminal bacteria into dysplastic regions [136] (see Intestinal Barrier Defects and 
Microbial Infiltration in CRC). IL-23 functions in part by up-regulating the Th17 response, and 
IL-23R blockade reduces IL-17A production [135], therefore it is likely that IL-23 imparts its 
effects by controlling the expression of IL-6, IL-22, and IL-17, but does not act on cancer cells 
directly [60]. 
COX-2 
 Cyclooxygenase-2 is an enzyme that converts arachidonic acid to prostaglandins, key 
mediators of inflammation [137]. Unlike COX-1, which is a housekeeping gene involved in 
producing prostaglandins at basal levels, COX-2 is not normally expressed by most cell types but 
can be strongly induced by a variety of different growth factors and pro-inflammatory cytokines 
[138]. Approximately 85% of human colorectal carcinomas and 50% of colonic adenomas 
exhibited elevated COX-2 expression [139-141], and COX-2 is up-regulated in intestinal 
adenomas from ApcMin/+ mice [142]. Correspondingly, a daily dose of aspirin or other non-
steroidal anti-inflammatory drug, which block COX-2 activity, over the course of 10-15 years 
can reduce the relative risk of developing CRC by up to 50% [143-146] and can reduce colonic 
adenoma size and number in FAP patients [147,148]. 
Mouse Models of Immunodeficiency in Colitis and Cancer 
 Several genetic mouse models of colitis have been interrogated regarding their 
microbiome patterns before, after, and during active inflammation, which can perturb the 
microbiota as oxidative stress and antimicrobial molecules increase during inflammation [149]. 
Mouse models of colitis, including FVB.mdr1a-/- [150], BALB/c.T-bet-/- X Rag2-/- [151,152], and 
IL-10R2-/- X TgfbrII-/- [153] mice, have been profiled using multiple methodologies inclusive of 
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culture-dependent and -independent techniques and revealed distinctive patterns with the gut 
microbiota. The Enterobacteriaceae Klebsiella pneumoniae and Proteus mirabilis were 
associated with colitis in T-bet-/- X Rag2-/- [152], while Bacteroides thetaiotaomicron was 
associated with disease in IL-10R2-/- X TgfbrII-/- mice [153], suggesting that a variety of genes 
may impact colonization and fitness of specific gut microbes in the setting of an inflamed 
epithelium and genetic immune perturbations. Remarkably, the colitigenic microbiota of the T-
bet-/- X Rag2-/- mice is transmissible to WT mice by co-housing [151,152,154]. The T-bet-/- X 
Rag2-/- mice develop colonic adenocarcinoma after 6 months of age, but all signs of dysplasia are 
prevented by keeping the mice on a cocktail of antibiotics [155], suggesting that the microbiota 
is responsible for driving colonic tumorigenesis in this model. 
 
The Role of the Gut Microbiota in Colorectal Cancer 
Associations between Single Bacterial Species and Cancer 
 The best characterized association between a single bacterial species and cancer is that of 
Helicobacter pylori and gastric cancer, a discovery that resulted in a Nobel Prize for the co-
discoverers Barry J. Marshall and J. Robin Warren [156]. H. pylori is the most common etiologic 
agent in infection-related cancer, and accounts for 5.5% of all cancers globally [157]. Most 
individuals that harbor H. pylori, approximately 50% of the world’s population [24], do not 
develop peptic ulcers or cancer, but there is a significant amount of data to support a causal 
relationship between H. pylori and gastric cancer based largely on epidemiology and case-
control studies [158]. A series of meta-analyses that assessed the association between gastric 
cancer and H. pylori, despite finding that approximately 50% of studies produced negative 
results, independently came to the conclusion that the association has an odds-ratio of 
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approximately 2.0 (range 1.92 to 2.56) [158-164]. Although there is conflicting evidence on 
whether or not Helicobacter eradication therapy reduces incidence of gastric cancer [165], at 
least one study convincingly demonstrates that successful eradication of H. pylori in gastric 
mucosa-associated lymphatic tissue lymphoma can successfully treat 80% of patients with early 
stage lymphomas [166]. Beyond epidemiological data, there is evidence for molecular 
mechanisms that link H. pylori infection with cancer. The development of gastric cancer is 
believed to be a multi-step process which includes superficial gastritis, chronic atrophic gastritis, 
and proceeds to metaplasia, dysplasia, and then carcinoma [167]. H. pylori is involved in the 
early stages of this process, causing chronic active gastritis and atrophic gastritis (Correa’s 
hypothesis) [15,16]. Upon bacterial attachment to the epithelial cell, a number of bacterial 
proteins are secreted into the cell by the type IV secretion system, including CagA and the VacA 
toxin. VacA induces vacuole formation in the cell that stimulates apoptosis of the epithelial cell 
[168]. CagA becomes tyrosine-phosphorylated by endogenous kinases and then causes the 
sustained activation of SHP-2, ERK1/2, and Src kinase [169,170], leading to actin cytoskeletal 
changes in the cell that may promote proliferation [16]. 
 There is a long-standing clinical observation that links Streptococcus bovis (now known 
as Streptococcus gallolyticus) infection with endocarditis and CRC [171]. Patients that present 
with S. gallolyticus endocarditis or septicemia are routinely screened for the presence of 
colorectal cancer, because 60% of S. gallolyticus-infected patients are found to have a 
concomitant adenoma or carcinoma [172]. The underlying pathophysiology of this strong 
association is not understood [173-175], but it may be the result of decreased epithelial barrier 
function at the site or colonic adenomas or carcinomas that allows streptococcal species to enter 
into the circulation [136]. 
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 Growing evidence suggests a role for adherent-invasive strains of Escherichia coli in 
driving CAC. Strains of E. coli that carry the polyketide synthase (pks) pathogenicity island 
cause DNA double-strand breaks and activation of the DNA damage checkpoint pathway, 
leading to cell cycle arrest and cell death in vitro [176]. The pks island encodes the polyketide-
polypeptide genotoxin Colibactin. E. coli harboring Colibactin induced phosphorylated H2AX 
foci in mouse enterocytes in vivo, as well as the appearance of micronuclei, aneuploidy, ring 
chromosomes, and anaphase bridges, suggesting that Colibactin induces breakage-fusion-bridge 
cycles and chromosomal instability [177]. A recent study showed that monocolonizing germ-
free, AOM-treated, Il10-/- mice with a pks-containing strain of E. coli resulted in enhanced tumor 
multiplicity compared to Enterococcus faecalis –monocolonized control mice despite similarly 
high levels of colitis [178]. Remarkably, intestinal tumorigenesis could be abolished in this 
model by deletion of the pks island in the E. coli strain [178]. Although previous studies have 
observed an association between E. coli and CRC [179] and Crohn’s disease [180], pks-positive 
E. coli were found to be enriched in both IBD and CRC cohorts [178], suggesting that this DNA-
damaging bacterium may be a clinically relevant etiologic agent in human CRC. 
 Enterotoxigenic Bacteroides fragilis (ETBF) secretes the metalloprotease toxin B. fragilis 
toxin (BFT) and is associated with inflammatory diarrheal disease in young children [181]. A 
stool-based quantitative PCR-based study found that ETBF was found at a higher prevalence in 
CRC patients compared to healthy individuals in a Turkish cohort [182]. This finding raised the 
possibility that ETBF could have a role in promoting tumorigenesis in this population, as other 
studies have shown that ETBF induces c-myc expression and proliferation when co-cultured with 
a colon carcinoma cell line [183], triggers the cleavage of E-cadherin and enhances β-catenin 
signaling in vivo [184], and that it induces colitis in WT mice [185]. In a seminal study, Cynthia 
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Sears and colleagues showed that ApcMin/+ mice colonized with ETBF developed severe colitis 
and a significantly increased colonic tumor load compared to control mice colonized with a non-
BFT-containing strain of B. fragilis [135]. The colonic lamina propria of ETBF-colonized mice 
were enriched for Th17 and γδ T lymphocytes, and antibody-based blockade of IL-17 
ameliorated colonic tumorigenesis in this model [135]. Therefore, inflammation as a result of 
response to the BFT toxin drives inflammation and carcinogenesis. In addition to this 
inflammatory mechanism, ETBF was found to induce spermine oxidase (SMO), a polyamine 
catabolic enzyme, leading to the generation of reactive oxygen intermediates, and DNA damage 
in vitro, and inhibition of SMO reduces ETBF-mediated inflammation in ApcMin/+ mice [186]. It 
has been proposed that ETBF, perhaps like pks-containing E. coli, is an “alpha-bug;” capable of 
introducing DNA damage, promoting IEC proliferation, driving tumor-promoting inflammation, 
and perhaps influencing the microbiota as whole to drive colonic tumorigenesis [187]. 
Evidence for a Role of the Microbiota in CRC from Gnotobiotic Mice 
  Gnotobiotics is the science of well-controlled microbial environments within and for 
biological specimens, encompassing the generation and maintenance of both germ-free (GF) and 
defined microbial community animals [188]. While gnotobiotic mice are discussed here, there 
are gnotobiotic fish, flies, rats, pigs, and foals. Gnotobiotic techniques have been essential to 
mechanistically interrogate host–microbiota interactions in mice [189]. Rederivation of any 
combination of genetic mutant mice is possible via embryo transfer into GF pseudopregnant 
mice or aseptic harvesting of a gestational uterine package and transfer of the fetuses to a GF 
foster female. It is important to realize that although GF mice do not harbor live bacteria or 
archaea, they are not naive to microbial-associated molecular patterns, as they encounter them in 
their sterilized (by autoclave or irradiation) food, water, and bedding. Microarray-based 
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comparisons of host tissues from GF mice and their conventional counterparts have been a 
successful approach to understand the broad impact of the microbiome on physiology 
[78,190,191]. Microarrays of GF and conventionalized mice even have shown that the gut 
microbiota modulate host gene expression post-transcriptionally by altering expression of host 
microRNAs within the small and large intestine [192]. 
 The first evidence that the microbiota may have a role in CRC came from gnotobiotic 
experiments in GF rats that showed a higher incidence of CRC in conventionally-raised 
compared to GF rats [193]. Since then, there have been a number of studies in genetically 
engineered mice predisposed to CRC showing a lower incidence of disease under GF conditions. 
For instance, T cell receptor beta-chain and p53 double-knockout (Tcrβ-/- X p53-/-) mice showed 
no incidence of intestinal adenocarcinoma under GF conditions, whereas ileocecal and cecal 
adenocarcinomas were detected in 70% of the conventionalized group [194]. Tgf-β1-/- mice 
normally develop CRC, but are free from inflammation, hyperplasia, and carcinoma when reared 
germ-free, but intestinal lesions re-appear when the mice are exposed to Helicobacter hepaticus 
[195]. Similarly, Rag2-/- mice, which lack an adaptive immune system, are also free from 
inflammation and all signs of hyperplasia under GF conditions, but develop inflammation and 
intestinal carcinoma in the presence of Helicobacter hepaticus [196]. ApcMin/+ mice show a 
reduction in both small intestinal and colonic tumors under GF versus conventional conditions, 
and the gut microbiota has been found to trigger the c-Jun—JNK and STAT3 signaling pathways 
to accelerate tumor growth in this mouse model [197]. 
 There are a number of studies that explore the contribution of the gut microbiota to colitis 
and CRC in IL-10-deficient mice. IL-10 was initially identified to be produced by T helper type 
2 (Th2) cells, B cells, and macrophages to inhibit Th1 cell functions, and was subsequently 
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found to be a potent suppressor of macrophage activation and generally a strong anti-
inflammatory cytokine [198,199]. Consequently, Il10-/- mice develop chronic colitis [198] and 
are also predisposed to developing CRC. Germ-free Il10-/- mice developed significantly less 
colitis than conventionally raised Il10-/- mice [200]. Il10-/- mice mono-associated with 
Enterococcus faecalis developed colitis and colonic adenocarcinoma, but both GF mice and mice 
mono-associated with a number of control strains of bacteria did not develop any signs of 
carcinoma [200]. IL-10-deficient mice that are treated with the carcinogen AOM develop colitis 
and CRC under conventional conditions, but do not develop any intestinal inflammation or 
dysplasia under GF conditions [201]. Two related studies suggest that colonization by 
Helicobacter hepaticus, a common symbiont of the mouse gut microbiota, specifically is 
required to drive AOM-induced colon tumors in Il10-/- mice [202,203]. Similarly, mono-
association with a Colibactin-positive, but not Colibactin-negative, strain of E. coli in AOM-
treated, Il10-/- mice drives CAC [178] (see Associations between Single Bacterial Species and 
Cancer). These studies indicate that the microbiota is required for the development of colonic 
tumors in a number of different mouse models and so raise the question: What microbial factors 
are responsible for contributing to tumorigenesis? 
Microbial Products that Contribute to Tumorigenesis 
 Most studies on bacterial contributions to cancer have been approached from the 
perspective of the inflammatory response to the microbe (see The Role of Inflammatory 
Responses to the Microbiota in Cancer), but recent research points to possible direct 
contributions of microbial metabolites to the carcinogenic process. 
 Early work in rats showed that conventionally raised but not GF animals develop CRC 
when given the plant glycoside carcinogen cyasin, however GF rats develop colon tumors when 
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given the downstream active metabolite of cyasin, methylazoxymethanol (MAM) [204]. The 
conversion of cyasin to its carcinogenic form MAM was found to be imparted by β-glucosidase, 
an enzyme that is encoded by the microbiota [204]. In subsequent decades, it has been found that 
the microbiota can convert latent carcinogens into bioactive compounds through the action of a 
number of bacterial enzymes including β-glucosidase, β-glucuronidase, 7-α-dehydroxylase, 
azobenzene reductase, and nitroreductase [30,205]. 
β-glucuronidase 
 Many compounds that are metabolized in the liver become conjugated to glucuronic acid 
and then secreted into the small intestine via the bile. Bacterial β-glucuronidase in the colon 
hydrolyzes these conjugates, releasing the parent compound. For example, one of the most 
commonly used colonic carcinogens, AOM, is hydrolyzed into the activated procarcinogenic 
metabolite MAM in the liver, conjugated with glucuronic acid, and then secreted through the bile 
into the small intestine [206]. When this compound becomes introduced to the colonic 
microbiota, β-glucuronidase activity converts it to its carcinogenic form by removing the 
glucuronide group. The activity of additional, yet-uncharacterized bacterial enzymes also 
metabolize MAM into methyldiazonium and a reactive methyl-carbonium ion [207]. The 
inhibition of β-glucuronidase in AOM-treated rats significantly reduced colon tumor load [208]. 
In another example, the colon cancer chemotherapeutic CPT-11 causes severe diarrheal disease 
when reactivated into the toxic form by β-glucuronidase, and β-glucuronidase inhibitors block 
removal of the glucuronide group and thereby prevent toxicity caused by this substance [209]. 
As might be expected, populations at high risk for CRC show high levels of β-glucuronidase 
activity in stool [210]. Rats fed a high-fat diet, associated with a high risk for CRC, show 
increased β-glucuronidase activity in cecal and colonic contents [211]. Conversely, diets high in 
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fiber and bran are associated with decreased risk of CRC and decreased β-glucuronidase activity 
in rats [212] and in humans [213].  
7-α-dehydroxylase 
 7-α-dehydroxylase is a microbial enzyme that converts the bile acid cholate into 
deoxycholic acid (DCA). DCA has been shown to cause DNA damage and apoptosis in IECs 
[214]. High levels of fecal DCA are associated with increased CRC risk [215], and 7-α-
dehydroxylase activity is higher in stool from CRC patients relative to healthy control 
individuals [216]. Bile acids can disrupt the integrity of the colonocyte cell membrane, resulting 
in the release of arachidonic acid and prostaglandin E2 (PGE2), which can drive proliferation in 
IECs. Secondary bile acids can also contribute to cell necrosis, hyperplasia, proliferation, DNA 
damage, and apoptosis [14]. 
Reactive Oxygen Intermediates 
 Reactive oxygen intermediates are derivatives of molecular oxygen and include 
superoxides, hydrogen peroxide, hypochlorous acid, singlet oxygen, and hydroxyl radicals. Some 
intestinal microbes, for example Enterococcus faecalis, produce substantial amounts of 
extracellular superoxide and hydrogen peroxide that have been shown to damage DNA and 
promote chromosomal instability in IECs in vitro [217-219]. The use of superoxide dismutase 
and γ-tocopherol, which block the production of ROI, in co-cultures of E. faecalis and IECs 
reduced levels of chromosomal instability [218]. Of course in vivo, activated macrophages and 
neutrophils [220-222] as well as epithelial cells and pre-malignant cells [223,224] also produce 
significant amounts of ROI, and therefore it can be difficult to determine how much ROI is 
contributed by the host versus the microbes themselves. During chronic inflammation, the DNA 
damage caused by ROI leads to mutations, deletions, and sister chromatid exchanges, which all 
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contribute to chromosomal instability and drive the carcinogenic process [14]. 
 Approaches aimed at reducing the production of ROI or the inhibition of nitric oxide 
synthase, which produces reactive nitrogen species, have been successful at reducing DNA 
damage and preventing tumorigenesis [221,223-225]. Mice that are deficient in both glutathione 
peroxidase enzymes Gpx1 and Gpx2, the major enzymes responsible for reducing 
hydroperoxides in the intestine, develop cancer with a penetrance of 25% under conventional 
conditions, less than 9% under specific pathogen-free conditions, and no tumors were observed 
under GF conditions [226]. 
N-nitroso Compounds, Heterocyclic Amines, and other Products 
 Nitrate in the diet is converted to nitrite by the intestinal microbiota [14], and nitrite 
reacts with amines, amides, and methylurea to produce nitric oxide compounds, carcinogenic 
DNA-alkylating agents [227,228]. Furthermore, experiments using germ-free rat have 
demonstrated that N-nitrosation in the colon is dependent on the gut microflora, the products of 
which have been shown to have carcinogenic properties [229,230]. Heterocyclic amines that are 
produced when meat is cooked at high temperatures have been implicated in a number of 
gastrointestinal cancers [30]. Recent studies have shown that the production of the active 
carcinogenic form of these compounds is dependent upon the enzymatic activity of the intestinal 
microbiota [231-234]. 
 Certain members of the microbiota that have been demonstrated to promote 
tumorigenesis produce carcinogenic compounds. Specifically, enterotoxigenic B. fragilis 
produces B. fragilis toxin, a metalloproteinase that cleaves E-cadherin [185] and contributes to 
colonic tumorigenesis in a mouse model [135], strains of E. coli that encode the pks 
pathogenicity island can induce DNA double strand breaks in eukaryotic cells and promote CRC 
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[176-178], and Helicobacter pylori encodes CagA and VacA among other secreted proteins that 
contribute to carcinogenesis in gastric adenocarcinoma [15,164,235-237] (see Associations 
between Single Bacterial Species and Cancer). 
Bacteria that Show Protective Effects in CRC 
 Just as certain members of the gut microbiota promote carcinogenesis, other bacteria 
show evidence of having a protective effect against cancer. For example, the daily administration 
of Lactobacillus acidophilus to ApcMin/+ mice results in decreased tumor multiplicity and size 
[238]. Similarly, AOM-treated rats fed L. acidophilus had decreased aberrant crypt foci (ACF) 
[239], L. acidophilus in combination with Bifidobacterium longum inhibited colonic 
tumorigenesis induced by dimethylhydrazine (a derivative of AOM) [240,241], and 
administration of Lactobacillus rhamnosus with Bifidobacterium lactis in AOM-treated rats 
decreased colonic tumor load [242]. Some bacteria can inhibit the activity of enzymes that 
produce carcinogens. For example, AOM-treated rats that were fed B. longum and an inulin 
derivative had decreased colonic ACF and reduced β-glucuronidase activity [243]. The co-
administration of L. acidophilus and Lactobacillus casei can decrease the enzymatic activity of 
β-glucuronidase, azoreductase, and nitroreductase in rats [244] and in humans [245]. L. casei can 
prevent DNA damage and tumorigenesis induced by the carcinogen methylnitronitrosoguanidine 
[246], and can metabolize a number of heterocyclic amines [247], and thereby prevent DNA 
damage in the colon and liver of rats [248]. Similarly, B. longum has been shown to have 
protective effects in rats against heterocyclic amine-induced colon, mammary, and liver 
carcinogenesis [249]. The high-potency probiotic preparation CSL#3 reduces signs of colitis and 
delays dysplasia in a rat model of CAC [250,251], and administration of the probiotic 
combination of L. rhamnosus GG and B. lactis Bb12 improved clinical biomarkers in human 
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colon cancer patients [252]. In addition to the above in vivo studies, there are many in vitro 
studies demonstrating anti-proliferative effects of specific bacteria: Bifidobacterium adolescentis 
can inhibit the production of TNF-α and the activity of β -glucuronidase and β -glucosidase, and 
reduce the proliferation of several human cell lines [253]; Bacillus polyfermenticus adheres to 
Caco-2 cells and confers a dose-dependent inhibition of proliferation [254]; Strains of lactic acid 
bacteria (LAB) reduce the growth and viability of HT-29 cells [255]; A number of 
Bifidobacterium species and Lactobacillus species can inhibit the growth of the MCF7 breast 
cancer cell line [256]. 
Probiotics 
 Probiotics are living microbes that can contribute to the health of the host. The species of 
probiotics that are most frequently used are Lactobacillus spp., Bifidobacterium spp., and LAB 
[36] and, in fact, most of the bacteria that show evidence of a protective effect against cancer are 
commonly-used strains of probiotics. Generally, probiotics do not become established members 
of the microbiota, but rather only persist during the time of dosage and shortly thereafter [257]. 
There are several mechanisms by which probiotics might impart a protective effect against 
carcinogenesis: the binding or degradation of carcinogens; the inactivation of microbial enzymes 
involved in procarcinogen activation; the production of anti-tumorigenic compounds; direct 
inhibitory effects on proliferation; the enhancement of the anti-tumor immune response; the 
production of biofilms that prevent the attachment or invasion of pathogenic bacteria; out-
competing pathogenic bacteria [36,258]. 
 A principle metabolic product of probiotic bacteria, and the gut microbiota as a whole, is 
the short chain fatty acid (SCFA), which includes butyrate, propionate, and acetate. These are 
produced by the fermentation of dietary fiber and starch. SCFA serves as the primary energy 
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source for colonocytes [259], influences immune responses and protects against inflammatory 
disease [260], and is involved in recovery from intestinal injury [259,260]. SCFA promotes cell 
cycle arrest and apoptosis in cultured IECs [261] by the up-regulation of Bak and down-
regulation of Bcl-xL through the mitochondrial pathway of apoptosis [262,263]. Butyrate 
induces histone hyperacetylation [264] by inhibiting histone deacetylase activity [265,266], thus 
explaining in part its pro-apoptotic effects [267]. Therefore, SFCA is likely a key molecule that 
contributes protective effects against cancer by probiotics. 
 There is a 15 to 20 year time interval from the appearance of pre-cancerous lesions to the 
development of carcinoma in colon cancer, so although much work remains to determine the full 
extent of its efficacy, probiotics may be an effective therapy to prevent or delay CRC in patients 
that are predisposed to the disease [36,268-270]. 
Intestinal Barrier Defects and Microbial Infiltration in CRC 
 A unique feature of dysplastic intestinal lesions is the local loss of intestinal barrier 
function. This is explained in part by the lack of mucus production because of decreased 
differentiation into goblet cells, and also by the loss of tight junctions between epithelial cells. 
As a result, dysplastic lesions are prone to infiltration by the luminal bacteria of the intestine. 
Indeed, disruption of the mucus layer renders mice susceptible to intestinal inflammation 
[45,271,272], which progresses to CAC [273] and the accelerated adenoma growth that is seen in 
the context of the ApcMin/+ genotype [274]. Interestingly, the absence of local barrier function at 
tumor sites in ApcMin/+ mice results in the translocation of microbial products across the 
epithelium and increased IL-23 expression [136]. IL-23 is a key cytokine in driving 
tumorigenesis in response to microbial infiltration, because its inactivation results in decreased 
tumor number and size and reduced levels of other pro-inflammatory cytokines [136].  
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Thesis Summary 
 This thesis reports on the characterization of the colorectal tumor microbiota and 
describes the functional contribution of members of the microbiota to the tumor 
microenvironment. In Chapter 1, we introduce PathSeq, a computational tool that is designed to 
analyze deep-sequencing datasets such as human whole-genomes and transcriptomes for the 
presence of microorganisms. PathSeq removes human sequences by computational subtraction 
before identifying microbe-derived sequences, and therefore is capable of identifying the 
presence of any microorganism including previously unsequenced, novel microorganisms. 
PathSeq also includes a module that performs a metagenomic analysis by calculating the relative 
abundance of each bacterial taxon present in the sample. In Chapter 2, we use the metagenomic 
analysis module of PathSeq to characterize the colorectal cancer microbiome using whole-
genome sequencing of CRC tumor and adjacent-normal tissue pairs. As a result of this analysis, 
we discovered a strong enrichment of Fusobacterium species in CRC tumors. Finally, in Chapter 
3, we introduce Fusobacterium species and other members of the CRC microbiome to ApcMin/+ 
mice, and find that Fusobacterium induces an NF-κB inflammatory response in the tumor 
microenvironment and accelerates intestinal tumorigenesis. 
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Abstract 
Many human diseases are believed to be caused by undiscovered pathogens [1,2]. The 
advent of next-generation sequencing technology presents an unprecedented opportunity to 
identify pathogens in hitherto idiopathic diseases. Here we present PathSeq, a highly scalable 
software tool that performs computational subtraction on high-throughput sequencing data to 
identify non-human nucleic acids that may indicate candidate microbes. PathSeq exhibits high 
sensitivity and specificity in its ability to discriminate human from non-human sequences using 
both simulated and experimental transcriptome and whole-genome sequencing data. PathSeq is 
implemented in a cloud-computing environment making it readily accessible by the scientific 
community. 
 
 
Introduction 
Previously our group and others have developed a computational approach to pathogen 
discovery, sequence-based computational subtraction [3-6]. This method is based on the premise 
that infected tissues contain both human and microbial nucleic acids and that novel pathogen-
derived sequences can be detected after subtracting human sequences. This unbiased approach to 
pathogen discovery is an advance over targeted PCR or pan-microbial array methods because it 
requires no sequence information ab initio about the organism being sought. However, 
performing computational subtraction at any significant scale was initially cost-prohibitive as 
this method requires a large number of input sequences, given that any pathogen present is likely 
to have low nucleic acid representation relative to that of the human host. 
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The recent development of next-generation sequencing methods [7,8], however, has 
made computational subtraction-based pathogen discovery a viable option. For example, 
massively parallel pyrosequencing combined with computational subtraction has resulted in the 
discovery of novel viruses in human disease: Merkel cell polyomavirus in Merkel cell carcinoma 
[9] and a novel Old World arenavirus in a cluster of patients with fatal transplant-associated 
disease [10]. Indeed, the past few years have seen steep drops in price and increases in 
throughput for next-generation sequencing technologies, and these trends are expected to 
accelerate in the near future [7,8]. However, this advancement in technology brings with it new 
computational challenges. Analyzing sequence data using the computational subtraction method 
is computationally expensive relative to most other next-generation sequencing analyses because 
it requires subtractive alignments to several large reference databases using local alignment 
algorithms such as BLAST. 
Here we present PathSeq, a comprehensive computational tool for the analysis of the 
non-host portion of resequencing data that is capable of detecting the presence of both known 
and novel pathogens as well as any resident microorganisms. PathSeq runs efficiently on 
sequence datasets of any size in a scalable and completely reproducible fashion because it is 
developed on a parallel computing architecture and is implemented in a cloud-computing 
environment. The PathSeq software package is available for public use in the form of a machine 
image for cloud computing, which can be launched and monitored using no more than a basic 
laptop computer. We believe that PathSeq opens the way for a new large-scale effort in pathogen 
discovery by any researcher with access to deep sequencing data from human tissue. 
 
 
	   52 
Results and Discussion 
The PathSeq process begins with a subtractive phase in which input reads are subtracted 
by alignment to human reference sequences (Fig. 1-1a), and continues with an analytic phase in 
which the remaining reads are aligned to microbial reference sequences and assembled de novo. 
The input reads are first filtered to remove low quality, duplicate, and repetitive sequences. The 
initial subtractive alignments are performed using the rapid short read aligner MAQ [11] against 
five reference human sequence databases, including both genomic DNA and transcriptome 
references (see Material and Methods). At the end of each subtractive alignment step, mapped 
reads are discarded and unmapped reads are subjected to further subtractive analyses. In the final 
steps, the residual reads are aligned to two additional human reference databases first using the 
Mega BLAST algorithm and then BLASTN. This identifies alignable reads with additional 
mismatches and/or short gaps that are not aligned by MAQ. The set of reads which remain 
unmapped after the subtractive phase are candidate non-human, pathogen-derived reads. A 
similar schema may be used for other host organisms by substituting the appropriate reference 
genome databases. 
The analytic phase of PathSeq is composed of several steps that are performed in parallel 
(Fig. 1-1b). To identify previously sequenced microbes, all unmapped reads are aligned to 
reference viral, bacterial, and fungal sequence databases by BLASTN and BLASTX. To assess 
the bacterial composition of a sample containing a rich microbiome, PathSeq performs a 
metagenomic analysis by aligning all unmapped reads to the complete collection of currently 
sequenced whole bacterial genomes and quantifying bacterial representation by a measure of 
both the total number of aligned reads and the bacterial genome coverage (see Materials and  
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Figure 1-1. The PathSeq workflow. (a) Conceptual workflow of the subtractive phase of PathSeq. The size of the 
read set (orange bars) is proportional to the number of reads at the indicated step in a typical run of the method. The 
black dots in the bars represent pathogen-derived sequences which become progressively concentrated. The steps in 
this conceptual workflow have been reordered for concision (see Materials and Methods for actual ordering). (b) 
Conceptual workflow of the analytic phase of PathSeq. The asterisk indicates the unmapped readset that is carried 
over from the subtractive phase. 
	   54 
Methods, Supplementary Tables 1-1 and 1-2). To increase the likelihood of discovering a 
novel organism, all unmapped reads are de novo assembled using the short read assembler 
Velvet [12]. The formation of large contigs composed of several unmapped reads that do not 
possess significant alignment similarity to any sequence in the reference databases may be 
suggestive of a previously undetected organism. 
To demonstrate the utility of PathSeq, we used simulated data to assess the ability of the 
method to (i) efficiently subtract human-derived sequences and (ii) minimize the subtraction of 
microbe-derived sequences (Fig. 1-2a). We created a simulated sequence dataset by combining 
sequences generated from a reference human transcriptome database and several virus genomes 
(Supplementary Fig. 1-1). Twenty million 100-mers were randomly generated from the 
reference transcriptome. The simulated virus reads were generated from twelve viral genomes; 
each viral genome was substitutionally mutated randomly at twelve distinct rates (0, 1, 5, 10, 20, 
30, 40, 50, 60, 70, 80, and 90 percent), to simulate unknown viruses at different evolutionary 
distances from known viruses, producing 1,000 reads per mutated genome for a total of (12 x 12 
x 1,000) 144,000 virus reads. 
After the subtractive steps of the PathSeq pipeline, all 20 million human transcriptome-
derived reads were correctly identified as human, and only 1,122 (0.78%) virus genome-derived 
reads were subtracted (Fig. 1-2a). Of these 1,122 reads, 1,120 were identified as repetitive 
sequences and the remaining 2 reads were subtracted because of alignment similarity to the 
human genome (Supplementary Table 1-3). 
To model the performance of PathSeq on low-quality sequence data, we introduced 
“sequencing errors” into this same readset based on the distribution of actual Illumina 
sequencing errors and found that this did not significantly affect the performance of PathSeq  
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Figure 1-2. PathSeq performance on simulated and experimental sequence data. (a) Reads were generated by 
sampling random 100-mer sequences from a human transcriptome database to produce 20 million reads, and from a 
set of twelve virus genomes each substitutionally mutated at twelve distinct rates, generating 144,000 reads (see 
Supplementary Fig. 1-1). The blue bars represent the number of human reads remaining after the indicated step in 
the PathSeq workflow, and the red squares connected by a line represent the remaining viral reads. (b) We applied 
whole-genome sequencing data from a human ovarian tumor and (c) one lane of total-RNA transcriptome 
sequencing from HeLa cell lines to PathSeq. The inset in panel c shows that the 30,790 reads remaining after the 
subtractive phase of PathSeq are predominantly composed of HPV-18 sequences. 
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(Supplementary Fig. 1-2, Supplementary Table 1-4, Materials and Methods). With the 
exception of human rhinovirus A, which contained many repetitive sequences, greater than 97% 
of all non-mutated, virus-derived reads were correctly identified by alignment to the viral 
nucleotide database, and over 50% were still correctly identified at a substitutional mutation rate 
of over 20% (Supplementary Fig. 1-3a). Sequence alignment following de novo assembly 
allowed the identification of sequences with an even higher mutation rate (Supplementary Fig. 
1-3b). We note that the presence of large, unidentifiable contigs in experimental sequence data 
could suggest the presence of a novel microbe lacking sequence homology to known microbes, 
and propose that such a result should justify follow-up by PCR, 3’- or 5’-RACE, and Sanger 
sequencing. 
This notion of identifying the presence of microbes by contig formation prompted us to 
ask how many reads are required to form sufficiently large contigs. The probability of forming 
contigs from reads originating from a single genome is a function of two variables: (i) the size in 
base-pairs of the genome in question; and (ii) the number of reads derived from the genome. We 
simulated the ability of Velvet, the short read assembler that is used in PathSeq, to form contigs 
that are at least 1.75 times the size of the input reads from a genome by randomly generating 
reads from genomes of varying length (Supplementary Fig. 1-4). We found that there is a >75% 
chance of forming contigs from genomes as large as 20kb when only 20 reads are derived from 
the genome (using 100bp reads). This suggests that relying on contig assembly to indicate the 
presence of a novel genome may be a practical approach. 
We then tested the performance of PathSeq on a set of sequences representing many-fold 
coverage of the whole genome of a serous ovarian carcinoma tumor that was sequenced as part 
of The Cancer Genome Atlas (see Material and Methods). Starting with slightly more than 1.7 
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billion reads of 101 bp each, we first removed mapped reads following initial alignment to the 
reference human genome, and then performed stringent quality filtering to yield 26.3 million 
reads. We ran these sequences on PathSeq and were left with a final set of 13,019 reads after 
subtraction, less than 0.001% of the original reads (Fig. 1-2b). The analytic phase of PathSeq did 
not yield any evidence that the remaining reads were derived from a pathogen; rather they likely 
represented yet-uncharacterized regions of the human genome or sequencing artifacts. This 
substantial subtraction efficiency, 99.9992%, demonstrates that the performance of PathSeq on 
simulated data can indeed be extended to real, human whole-genome sequencing. 
We next generated sequence data from HeLa cervical cancer cell lines with the 
expectation of finding human papillomavirus (HPV) type18. We sequenced a cDNA library 
generated from total RNA isolated from HeLa cells on a single lane of Illumina sequencing, 
generating 10.3 million quality- and purity-filtered 76-bp reads. We applied this sequence data to 
PathSeq (Fig. 1-2c). Human-derived reads were efficiently subtracted during the subtractive 
phase such that 0.30% of input reads remained unmapped. Out of these 30,790 reads, 25,879 
were identified as HPV-18, leaving 4,911 non-human, non-HPV-18 reads. We then collected all 
of the HPV-18 reads and searched for those whose pair-mate aligned to the human reference 
genome. This allowed us to identify the integration site of the viral genome in a region of 
chromosome 8q24 between positions 128,300,300 and 128,310,400 just upstream of the MYC 
oncogene. 
One longstanding goal of computational subtraction is the identification and 
characterization of every read in a dataset. Although the sensitivity and specificity data for 
PathSeq are impressive, it still leaves 0.00076% of the ovarian whole-genome sequence reads  
and 0.013% of the HeLa RNA-Seq reads unaccounted for. This shortfall might be explained by 
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error-ridden sequences passing the quality filter, reads that map to the splice junction of rare 
splice variants in RNA-Seq data, or reads that map to regions of the human genome that have not 
yet been characterized. A number of groups have recently reported novel human genome 
sequences by de novo assembly of next-generation whole-genome sequence data [13,14] or by 
using a fosmid end-sequence pair mapping approach [15]. Ideally, these new sequences could 
form a subtractive database for PathSeq and help reduce the total number of unaccounted reads. 
However, by performing a simple Mega BLAST alignment of these sequences to microbial 
databases we find that many sequences from all three above-mentioned studies have perfect 
matches to known bacteria, fungi, and viruses, raising the question of whether they may contain 
novel microbes as well. Therefore, an essential next step in the improvement of computational 
subtraction-based methods is the creation of a reliable database of human genome scaffolds that 
extend the current human reference genome. 
Taken together, our results demonstrate the ability of PathSeq to identify both known and 
novel microorganisms in high throughput human resequencing data. Just as current metagenomic 
surveys of the world’s oceans and soils are yielding remarkable new organisms, so too do we 
expect to reveal new viruses, bacteria, and fungi in human tissue with important medical 
implications. We are making PathSeq available for public use at 
http://www.broadinstitute.org/software/pathseq/, and it is our hope that investigators will use this 
tool to join our efforts in pathogen discovery. 
 
 
Materials and Methods 
RNA-seq library construction from HeLa cells and sequencing 
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RNA was extracted from cultured HeLa cells according to the RNeasy Kit (Qiagen) 
protocol. cDNA sequencing library construction was performed as described previously [16], 
with noted modifications below. The cDNA library was sequenced on the Illumina Genome 
Analyzer II (GAII) platform. The mean fragment length was approximately 350 base pairs. One 
lane of paired-end, 76 base pair sequencing was performed, producing 38.5 million purity 
filtered reads, which yielded 10,304,513 high quality reads following quality filtering. 
 
Modifications made to the Illumina RNA-Seq protocol 
Total RNA (500 ng) was heated at 98ºC for 100 min in THE RNA Storage Solution (1 
mM sodium citrate, pH 6.4; Ambion/ABI, AM7000) to fragment the RNA to a mean size of 
~500 nucleotides. Quality of RNA fragmentations was assessed on a Bioanalyzer 2100 (Agilent). 
First-stand cDNA synthesis was performed by adding random hexamers (Invitrogen, 48190-011) 
to the RNA and heating at 70ºC for 10 min, and then immediately incubating at 50 ºC for 1 h 
upon addition of Superscript III reverse transcriptase (Invitrogen).  Second-strand synthesis was 
carried-out with E. coli DNA ligase and E. coli DNA polymerase I (Invitrogen) for 2.5 h at 16 
ºC. cDNA was purified using the MiniElute PCR Purification Kit (Qiagen) and evaluated using 
Bioanalyzer. End-repair, addition of adenine to the 3’ end of the DNA fragments, and adapter 
ligation was performed as described in Guttman et al., except a 2:1 molar ratio of adapter to 
DNA fragment was used during adapter-ligation. The resulting adapter-ligated fragments were 
purified on a 4% SeaKem LE agarose gel (Lonza) and a 400-500 base pair band was cut out of 
the gel and purified using the MiniElute kit. PCR was performed with Phusion DNA polymerase 
(Finnzymes) and adapter-specific primers using the following conditions: 2 min at 98 ºC; [10 s at 
98 ºC, 30 s at 65 ºC, 30 s at 72 ºC] for 13 cycles; 5 min at 72 ºC. Following PCR, a second round 
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of gel extraction was performed as described above, and the product was submitted for Illumina 
sequencing. 
 
The PathSeq workflow and cloud implementation 
The PathSeq pipeline is designed using the Apache Hadoop implementation of the 
MapReduce programming framework (http://hadoop.apache.org/mapreduce) and can be run on 
the Amazon Elastic Compute Cloud (EC2) (http://aws.amazon.com/ec2/) [17]. The workflow is 
comprised of three modules: pre-subtraction, subtraction, and post-subtraction. The pre-
subtraction module is simply a quality filtering step and is run on the user’s local machine, 
whereas the subtraction and post-subtraction modules are executed on a Hadoop-based cluster 
(19 worker nodes and 1 master node) built using the Amazon Elastic Compute Cloud (Amazon 
EC2). 
Amazon’s Simple Storage Service (S3) file system (http://aws.amazon.com/s3/) is used to 
store the reference sequences and readset, and the config files and scripts are distributed across 
all nodes on the cluster using the Hadoop Distributed File System (HDFS). The reference 
sequences are continuously updated on the PathSeq system and users are given the option of 
substituting any built-in database with a database of their choice; however we provide data 
download dates for reference sequences used in experiments reported in this paper below.  
All processes are run on the Hadoop cluster in multiple map phases. The subtraction 
module comprises of two mappers. First, subtractive alignments are performed with MAQ 
(Release 0.5.0, default settings) against a set of six human sequence databases: the 1000 
Genomes Project female reference (ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/technical/reference/, downloaded 2009-04-11), the Ensembl 
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Homo sapiens cDNA database (ftp://ftp.ensembl.org/pub/current/fasta/homo_sapiens/cdna/, 
downloaded 2009-04-22), the human genome and transcriptome BLAST database 
(ftp://ftp.ncbi.nih.gov/blast/db/, downloaded 2009-05-25), and the set of three assembled human 
genomes available on NCBI (hs_alt_Celera, hs_alt_HuRef, hs_ref_GRCh37, 
ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/Assembled_chromosomes/, downloaded 2009-06-19). 
The next map phase is composed of three steps: RepeatMasker (http://www.repeatmasker.org/), 
MegaBlast, and BLASTN. First, the reads are applied to RepeatMasker (version open-3.2.8, 
libraries dated 2009-06-04), and any reads with three or more masked nucleotides are discarded.  
Subtractive alignments are next performed using MegaBlast (Blast Tools version 2.2.23, cut-off 
expect value 10-7, word size 16) to two human sequence databases: the NCBI Homo sapiens 
RNA database (ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/RNA/, downloaded 2009-11-20), and 
the Ensembl human genome reference 
(ftp://ftp.ensembl.org/pub/current/fasta/homo_sapiens/dna/, downloaded 2009-10-22). The final 
set of subtractive alignments are then performed with BLASTN (Blast Tools version 2.2.23, cut-
off expect value 10-7, word size 7, nucleotide match reward 1, nucleotide mismatch reward -3, 
gap open cost 5, gap extension cost 2) to the same two databases. A reduce phase gathers all 
remaining reads into one consolidated file which serves as input to the post-subtraction module. 
The post-subtraction module is also comprised of two mappers. The first mapper is a set 
of BLASTN (parameters as above) and BLASTX alignments (Blast Tools version 2.2.23, cut-off 
expect value 10-4, word size 3, matrix: BLOSUM62, gap open cost 11, gap extension cost 1) to 
viral (downloaded from NCBI Nucleotide (http://www.ncbi.nlm.nih.gov/nucleotide) using search 
term “‘viruses’[porgn:__txid10239]” on 2010-02-26), fungal (downloaded using the term 
“’fungi’[porgn:__txid4751]” on 2009-11-23), bacterial and archaeal 
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(ftp://ftp.ncbi.nih.gov/genomes/Bacteria/, downloaded 2010-03-30), and non-redundant protein 
(ftp://ftp.ncbi.nih.gov/blast/db/nr, downloaded 2010-04-05) reference sequences. This mapper 
also performs a de novo assembly (Velvet 0.7.31, k-mer size 21) on the full set of reads 
remaining from the previous map phase. The complete post-subtraction BLAST output files as 
well as the full set of unmapped reads and contigs are then uploaded and stored on the S3 storage 
system. 
The Amazon Machine Image (AMI) required to build the PathSeq Hadoop cluster is 
accessible from Amazon Web Services 
(http://www.broadinstitute.org/software/pathseq/).Pathseq is implemented in Python, Java, C++ 
and C shell, and has been tested on a Linux 2.6.18-194.8.1.e15 X86_64 system. 
 
PathSeq runtime and performance 
PathSeq analysis was performed using a cluster of 19 worker nodes and 1 master node, 
which were EC2 Large CPU instances (7GB of memory and 2 processor cores). Full analysis of 
HeLa cell RNA-Seq data described in this report was performed in approximately 13 hours (wall 
clock time) for a total price of $89 USD. The CPU time for this analysis was approximately 270 
hours. Actual runtime and cost may vary depending on congestion on the Amazon EC2, Internet 
traffic, and the method of data upload. Because of its parallel architecture, PathSeq can analyze 
substantially larger datasets in a similar timeframe simply by increasing the cluster size. 
 
Metagenomic analysis 
The metagenomic analysis module of PathSeq reports the relative abundance of bacteria 
and archaea. This analysis begins with a MegaBlast alignment of the readset against the 
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complete set of fully sequenced bacterial and archaeal genomes 
(ftp://ftp.ncbi.nih.gov/genomes/Bacteria/, downloaded 2010-03-30), reporting all hits with >90% 
sequence identity and >90% query coverage. The top 30 hits for each read are reported. Using 
these alignment results, classifications of each read are attempted at the phylum, then genus, then 
species level. If a given read cannot be classified uniquely at a given classification level (i.e. it 
has multiple hits to different reference sequences with equivalent E-values), then it is considered 
ambiguous and discarded from analysis at that level. Using species-level classifications, the 
fraction-genome-coverage is calculated for each species that received a hit, and this metric is 
used to quantify the relative abundance of a given species, normalized by the genome size. 
 
Generation and analysis of simulated sequencing data 
Simulated human transcriptome and virus sequence data. Twenty million 100-mers were 
randomly generated from a reference human transcriptome 
(ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/RNA/, downloaded 2009-11-20). Simulated virus 
reads were derived from twelve virus sequences: NCBI Nucleotide accession AY740741, 
CY000455, EU643590, FJ356716, FJ464337, GQ290462, GQ415051, NC_000883, 
NC_001405, NC_001806, NC_005179, and NC_007815. For each of these sequences, 
substitutional mutations were introduced at a frequency of 0%, 1%, 5%, 10%, 20%, 30%, 40%, 
50%, 60%, 70%, 80%, and 90%. In this process, nucleotides along the sequence are chosen at 
random with replacement (i.e. the same nucleotide can be chosen twice at random) and converted 
to a different nucleotide (for example, A is converted to C, G, or T). This produces 144 
sequences (12 input sequences, each mutated at 12 frequencies). For each of these 144 
sequences, 1,000 “reads” of length 100bp were produced at random. The resulting 144,000 
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simulated reads were pooled with the 20 million simulated human reads and analyzed on 
PathSeq. 
Contig formation simulations. In this experiment, “genomes” of size 200bp to 20,000bp in 
increments of 200bp were generated from the Human herpesvirus 5 genome (accession 
GQ466044). For each of these 100 “genomes”, two to twenty 100-mer sequences (“reads”) were 
generated at random. This process was performed eleven times. For each “genome” size, “read” 
number pair, Velvet assembly with k-mer size 21 was performed. The frequency with which 
contigs of at least 175bp were generated was recorded. 
 
Introduction of “sequencing errors” into simulated sequence data 
Sequencing errors were introduced into the simulated reads based on quality scores seen 
in a whole-genome sequence dataset of a glioblastoma multiforme (GBM) primary tumor 
(sequenced as part of The Cancer Genome Atlas; data available via the NCBI Short Read 
Archive (SRA) identifier SRX010704). The average quality score for each base along the length 
of the reads was calculated across the dataset and offset by -5 (Supplementary Fig. 1-3a). This 
was converted into a probability value and used to “mutate” our simulated reads (i.e. for a 
sequence error probability of 0.001, there is a 0.1% chance that the base will be converted to a 
different base). 
 
Human whole-genome ovarian tumor sequencing data 
The human ovarian tumor whole-genome sequencing dataset was sequenced as part of 
The Cancer Genome Atlas, and the data is available via the NCBI SRA identifier SRX010747. 
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This is a 101 base pair, paired-end sequence dataset with a nominal fragment length of 264 base 
pairs. 
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Genomic analysis identifies association of Fusobacterium with colorectal carcinoma 
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Abstract 
The tumor microenvironment of colorectal carcinoma is a complex community of 
genomically altered cancer cells, non-neoplastic cells, and a diverse collection of 
microorganisms. Each of these components may contribute to carcinogenesis, however the role 
of the microbiota is the least well understood. We have characterized the composition of the 
microbiota in colorectal carcinoma using whole genome sequences from 9 tumor/normal pairs. 
Fusobacterium sequences were enriched in carcinomas, confirmed by quantitative PCR and 16S 
rDNA sequence analysis of 95 carcinoma/normal DNA pairs, while the Bacteroidetes and 
Firmicutes phyla were depleted in tumors. Fusobacteria were also visualized within colorectal 
tumors using FISH. These findings reveal alterations in the colorectal cancer microbiota; 
however, the precise role of fusobacteria in colorectal carcinoma pathogenesis requires further 
investigation. 
 
 
Introduction 
Malignant tumors are complex communities of oncogenically transformed cells with 
aberrant genomes, associated non-neoplastic cells including immune and stromal cells, and 
sometimes microbes, including bacteria and viruses.  Several viruses that can integrate into the 
human genome directly cause cancer, such as human papillomavirus in cervical cancer [1] and 
Kaposi’s sarcoma-associated herpesvirus in Kaposi’s sarcoma [2]. In other cases, 
microorganisms lead indirectly to cancer through chronic inflammatory responses—a 
mechanism by which Helicobacter pylori contributes to both gastric cancer and MALT 
lymphoma [3,4]. 
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In the human distal gut, where microbial cells outnumber host cells nine-to-one [5], the 
microbiome can impart both beneficial and detrimental effects on host physiology contributing to 
health or disease susceptibility. Gut microbial communities (microbiota) may also influence the 
development of colorectal carcinoma [6-8]. Sears and Pardoll have recently introduced the 
concept of the “alpha-bug” – wherein select members of a microbial community, in addition to 
possessing virulence and pro-carcinogenic features, are capable of remodeling the microbiome as 
a whole to drive pro-inflammatory immune responses and colonic epithelial cell transformation 
leading to cancer [9]. 
We postulate that if the microbiota play an active role in the pathogenesis of colorectal 
carcinoma, then these microbes will be found within the tumor microenvironment, and the 
composition of the tumor microbiome will differ from that of adjacent non-neoplastic tissue. We 
have undertaken unbiased, sequence-based approaches, followed by cytological analysis, to 
probe the differences in the microbial composition of the colorectal carcinoma tumor 
microenvironment relative to adjacent non-neoplastic tissue.  We now report an association of 
Fusobacterium with the colonic mucosa of colorectal carcinoma. 
 
 
Results 
To determine the microbial composition of human colorectal cancer, we analyzed whole 
genome sequences of nine colorectal cancers and matched normal colons [10] using PathSeq, a 
computational subtraction pipeline that culls out candidate microbial sequences [11]. These 
presumed bacterial sequences were identified by alignment to known sequenced microbial 
genomes (Fig. 2-1a, Supplementary Fig. 2-1, Supplementary Table 2-1). PathSeq analysis 
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also identified the presence of virus sequences in these specimens including human herpesvirus 
7, however no significant differences in viral sequence levels were detected between tumor and 
normal DNA (Supplementary Table 2-2). Hierarchical clustering analysis of the species-
specific relative abundances of microbial sequences revealed that the microbial communities of a 
tumor and matched non-cancerous colon from a given patient were more similar to each other 
than are tumors or non-affected colon samples from different patients (Fig. 2-1b). This finding 
suggests that a patient’s intestinal ecosystem may be more significant in shaping the microbiota 
than the generic microenvironment of a colon tumor or normal colonic tissue. 
To identify bacterial species whose sequences are more abundant in colorectal tumors 
than in the matched, non-cancerous colorectal tissue, we applied a metagenomic biomarker 
discovery approach, LEfSe (Linear Discriminant Analysis (LDA) coupled with effect size 
measurements), which performs a non-parametric Wilcoxon sum-rank test followed by LDA 
analysis to assess the effect size of each differentially abundant taxon [12]. Using LEfSe, we 
found that Fusobacterium sequences were significantly enriched in the colorectal cancer 
metagenomes as were sequences from the family of Streptococcaceae (Fig. 2-1c, Fig. 2-1d, 
Supplementary Fig. 2-2).   
As our initial screen was performed on a sample size of 9 cases, we next examined a 
larger cohort of 95 paired specimens of colon cancer and normal colonic DNA to survey the 
colon cancer microbiome and validate the tumor-specific enrichment of Fusobacterium. We 
amplified ribosomal 16S rDNA by PCR using consensus primers from 95 tumor/normal pairs, 
followed by pyrosequencing to assess the relative abundance of DNA from bacterial species  
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Figure 2-1. Whole-genome sequencing analysis of the colorectal cancer microbiome. (a) Schematic of 
experimental and computational whole-genome sequencing analysis workflow. (b) Hierarchical clustering of 
phylotype relative abundance measurements demonstrates that microbial composition of tumor/normal pairs within 
individuals is more highly correlated than tumor/tumor pairs or normal/normal pairs from different individuals. 
Normal samples are shown in green, tumors are shown in purple. (c) Linear Discriminant Analysis (LDA) coupled 
with effect size measurements identifies Fusobacterium as the most differentially abundant taxon in colon tumor 
versus normal specimens by whole-genome sequencing in 9 individuals. Tumor-enriched taxa are indicated with a 
positive LDA score (black), and taxa enriched in normal tissue have a negative score (gray). Only taxa meeting an 
LDA significant threshold of 1.8 are shown. (d) Percent relative abundance for the genus Fusobacterium is depicted 
across all samples in the order of the labels in (b), demonstrating a tumor-enrichment in most individuals. 
 
 
(Fig. 2-2a). Overall, as was the case in our whole-genome sequence data, tumor/normal pairs 
from the same individual are much more highly correlated than tumor/tumor pairs or 
normal/normal pairs from different individuals (Fig. 2-2b). Colorectal tumors were associated 
with broad phylum-level changes including the depletion (i.e. reduced relative abundance) of  
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Figure 2-2. 16S rDNA sequencing analysis of the colorectal cancer microbiome. (a) Schematic of experimental 
and computational 16S rDNA sequencing analysis workflow. (b) Beta-diversity distances calculated using 
phylotype relative abundance measurements between all pairs of samples demonstrate that the microbial 
composition of tumor/normal pairs within individuals is more highly correlated than tumor/tumor pairs, 
normal/normal pairs, or tumor/normal pairs from different individuals. (c) Linear Discriminant Analysis (LDA) 
coupled with effect size measurements identifies Fusobacterium as the most differentially abundant taxon in colon 
tumor versus normal specimens by 16S rDNA sequencing in 95 individuals. Tumor-enriched taxa are indicated with 
a positive LDA score (black), and taxa enriched in normal tissue have a negative score (gray). Only taxa meeting an 
LDA significant threshold of 4.2 are shown. (d) A cladogram representation of data in (c). Tumor-enriched taxa are 
indicated in red, and taxa enriched in normal tissue are blue. The brightness of each dot is proportional to its effect 
size. 
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Firmicutes and Bacteroidetes, most prominently the Clostridia (Fig. 2-2c, Fig. 2-2d, 
Supplementary Fig. 2-3); however the overall diversity in the tumors relative to adjacent tissue 
was not significantly different (Supplementary Fig. 2-4a and Supplementary Fig. 2-4b). 
Consistent with our whole-genome sequencing results, the relative abundance of Fusobacterium 
was highly enriched in the population of tumor versus normal samples (Fig. 2-2c and Fig. 2-2d). 
However a tumor-enrichment for Streptococcaceae was not reproduced, most likely due to small 
sample-size in our initial whole-genome sequencing results. In addition, we analyzed patient 
metadata to identify correlations or possible confounding effects (including patient age, gender, 
ethnicity, tumor anatomic location, tumor purity, inflammation, necrosis, and vascularization), 
but only found a modest correlation with patient geographic location (Supplementary Fig. 2-5), 
as well as a correlation of higher microbial diversity with tumors of higher histological stage or 
grade (Supplementary Fig. 2-4c). The correlation of fusobacteria abundance with geographic 
location may either indicate a real geographic effect or else a confounder introduced by slightly 
differing sample collection protocols at the collection sites, for example time between surgery 
and freezing (see Materials and Methods). 
As we have shown that Fusobacterium species are enriched in colorectal cancer DNA 
and tissue, we sought associations that might suggest that fusobacteria are required for the 
survival or maintenance of colorectal cancer cells.  Because Fusobacterium species can invade 
colonic epithelial cells [13], we examined colorectal cancer cell lines and hepatic and lymph 
node metastases for evidence of fusobacterial DNA. Quantitative PCR analysis of 59 human 
colorectal cancer cell line DNAs revealed no significantly detectable Fusobacterium DNA, 
however these in vitro passaged cell lines are often cultured in the presence of antibiotics 
(Supplementary Table 2-3). Strikingly, however, when we examined surgically resected 
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colorectal cancer metastases, Fusobacterium was detected in 2 out of 11 cases (Supplementary 
Table 2-4). 
Given the increased abundance of Fusobacterium sequences in colon cancer DNA, we 
next asked whether Fusobacterium could be detected in histological sections of colon cancer, 
and if so, where. To address this question, we used 16S rDNA fluorescence in situ hybridization 
(FISH) oligonucleotide probes on colonic biopsy sections. Employing probeBase consortium 
16S rDNA probes that detect the majority of bacteria (EUB338) and members of the genus 
Fusobacterium (FUSO) [14,15], we performed FISH analysis on frozen (9 cases) and formalin-
fixed paraffin embedded  (12 cases) tissue sections from colorectal cancer and normal colon. The 
Fusobacterium probes detected bacteria in the colorectal cancer and normal tissue sections and 
were quantitated within the lamina propria and mucus (Fig. 2-3a); z-section stacks suggest that 
some of the imaged bacteria may reside intracellularly (data not shown). Consistent with the 
analysis of Fusobacterium DNA described above, FISH-detected fusobacteria were enriched in 
the colorectal cancer compared to the normal samples (Fig. 2-3b, Supplementary Fig. 2-7; see 
Supplementary Fig. 2-8 for a comparison of Fusobacterium quantitation across all 4 methods), 
in contrast to total bacteria counts which were more evenly distributed (Supplementary Fig. 2-
7). 
Finally, we sought to assess the specific Fusobacterium species that are enriched in 
colorectal carcinomas.  Based on the 16S ribosomal DNA sequences, 5 out of a total of 409 
operational taxonomic units (OTUs, a proxy for species) identified in our samples were classified 
as members of the Fusobacterium genus. By performing multiple sequence alignments using our 
5 OTUs along with 16S rDNA sequences from a reference set of 31 Fusobacterium species and 
constructing maximum likelihood trees, the OTUs were identified as most closely related to  
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Figure 2-3. Fluorescence in situ hybridization (FISH) detects enrichment of fusobacteria in colorectal tumors. 
(a) FISH using an Oregon-Green 488-conjugated ‘‘universal bacterial’’ 16S rDNA-directed oligonucleotide probe 
(EUB338, green) (top left) and Cy3-conjugated Fusobacterium (FUSO, red) (top right and bottom center)16S 
rDNA-direct oligonucleotide probe demonstrates the presence of bacteria and Fusobacterium within in the colonic 
mucosa of colorectal tumor samples. Representative images are shown with a 10 µm scale bar in the lower corner of 
each panel; white arrowheads mark bacteria. Epithelial cell nuclei were stained with DAPI. (b) To determine 
whether Fusobacterium was enriched in tumor versus normal pairs, 3 random 40X fields were chosen for scoring by 
an observer blinded to tumor/normal status, using selection criteria of mucosal tissue depth and a minimum of 5 
bacteria visualized by the EUB338 probe per field. Each dot represents data from either a tumor or normal sample 
from 9 tumor/normal paired cases. The mean, SEM, and p-values (calculated by a Wilcoxon matched-pairs signed 
rank test) are shown. 
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Fusobacterium nucleatum, Fusobacterium necrophorum, Fusobacterium mortiferum, and 
Fusobacterium perfoetens (Fig. 2-4a). The percent relative abundance in colorectal tumors 
versus normal colons of the two most abundant OTUs is shown in Fig. 2-4b, demonstrating that 
for most patients these OTUs are enriched in the tumor. Strikingly, only a subset of the cancers 
showed dramatic enrichment of Fusobacterium species, accounting for up to 89% of total 
bacterial DNA in some specimens; this result suggests that fusobacteria may be uniquely related 
to pathogenesis of subsets of colorectal cancer. The OTU with the greatest similarity to F. 
nucleatum was the most dominant phylotype identified within cancers, however some tumors 
contain more than one dominant species (Supplementary Fig. 2-9). 
 
 
Discussion 
In summary, genomic analysis of the microbiome of colorectal carcinomas reveals a 
significant enrichment of Fusobacterium species in these cancers, especially phylotypes with the 
greatest similarity to F. nucleatum, F. mortiferum, and F. necrophorum.  This enrichment is 
confirmed by histological analysis of tumor tissue, and also the identification of Fusobacterium 
DNA in colon tumor metastases. Our analysis also reveals broader changes in the tumor 
environment such as the depletion of the Bacteroidetes and Firmicutes phyla, most notably the 
order Clostridiales. Fusobacterium species may have a fitness advantage in the evolving tumor 
microenvironment resulting in an altered microbiota in accordance with the “alpha-bug” 
hypothesis. 
Interestingly, Fusobacterium species may be associated with inflammatory bowel 
diseases (IBD) including both ulcerative colitis and Crohn’s disease  
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Figure 2-4. Phylogenetic analysis identifies several Fusobacterium species in human colon cancer tissues. (a) 
Approximately-maximum-likelihood phylogenetic trees were constructed on the V3-V5 region of the 16S rDNA 
gene using 31 reference Fusobacterium species along with the five most prominent OTUs identified in colon cancer 
specimens (indicated in red). Nodes that have bootstrap support above 50% and 75% are indicated with a white and 
black dot, respectively. The mean percent relative abundance in tumor (T) and normal (N) of each OTU is indicated 
in parentheses. The full names of the reference strains appear in Supplementary Table 2-5. (b) The abundance of 
the indicated OTU relative to all other phylotypes in a given specimen is shown for the two most abundant 
Fusobacterium OTUs in tumors (x-axis) and normal colon tissue (y-axis); each point represents tumor and normal 
abundance data for a different individual. The lower-right quadrant of the graph highlights the substantial proportion 
of patients for whom the Fusobacterium abundance is >10% in tumors but <10% in the matched normal. 
 
[13,16,17], and IBD is a known risk factor, indeed one of three highest risk factors, for colorectal 
cancer.  Furthermore, consistent with our findings in colorectal carcinoma, others have reported 
that several Fusobacterium strains were associated with IBD, however the majority (69%) were 
specifically associated with F. nucleatum [13]. Therefore it is worth further exploration of a 
causal link between Fusobacterium spp. with inflammatory bowel disease and colorectal 
carcinoma pathogenesis. 
	   78 
F. nucleatum and other Fusobacterium species can elicit host pro-inflammatory response 
[18] and posses virulence characteristics that promote their adhesiveness to host epithelial cells 
[19,20] and their ability to invade into epithelial cells [13,21]. Therefore, our findings of a 
tumoral enrichment of Fusobacterium spp. in colorectal carcinoma suggest the possibility that 
these organisms may contribute to tumorigenesis, perhaps in a limited subset of patients, most 
conceivably by an inflammatory-mediated mechanism. Alternatively, it is possible that 
fusobacteria accumulate in the tumor microenvironment in the late stages of tumorigenesis and 
therefore do not have a significant role in tumor development. Our results do not prove a causal 
relationship between Fusobacterium and colorectal cancer; the establishment or repudiation of 
such a relationship will require further studies of colorectal cancer in both human subjects and 
animal models of the disease. Additionally, case-control studies comparing tumor microbiota to 
that of colonic epithelial tissues from healthy individuals will serve to demonstrate whether 
Fusobacterium species are more prevalent in individuals with colon cancer relative to the general 
population. 
In summary, our findings reveal species-specific alterations in the colorectal cancer 
microbiota, which may lead to microbiota-directed prevention, diagnostic, prognostic, and 
treatment strategies for these cancers. 
 
 
Materials and Methods 
Sample collection and preparation 
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Colorectal adenocarcinoma and adjacent non-affected tissue was obtained from the Vall 
d’Hebron University Hospital in Barcelona, Spain and Genomics Collaborative Inc. (GCI), using 
the sample collection protocols detailed below: 
Vall d’Hebron University Hospital 
All Frozen tissue samples were collected following the Standard Operating Procedures at the 
site. Participants were enrolled in the study prior to surgery, and informed consent was obtained 
by the surgeon. After arterial ligation and surgical removal of the tissues, the specimens were 
immediately transferred from the Operating Room to the Pathology suite and subsequently 
evaluated by the pathologist and, if possible, one fragment of healthy tissue and one of tumor 
were chosen and placed in a cryotube and frozen immediately in liquid nitrogen (time interval 
between specimen removal and freezing: maximum= 30 min.; median= 22 min.). The frozen 
tissue was stored at -80 °C until DNA extraction. All clinical data, captured on Case Report 
Forms, was double-data entered in to a clinical database. 
Genomics Collaborative Inc. 
All Frozen tissue samples were collected following the same Standard Operating Procedure at all 
collection sites, both within the US and in Vietnam. Participants were enrolled in to the study 
prior to surgery, and informed consent was obtained. After arterial ligation and surgical removal 
of the tissues, the tissue was transferred from the Operating Room to the Pathology suite. The 
time taken from surgical removal of the specimen until the time it was received for processing in 
the pathology suite, as well as the temperature at which it was transferred (room temp, or on ice) 
were recorded. The SOP required the Tissue Transmittal time (from removal to freezing of the 
sample) to ideally be between 30 to no more than 45 minutes. Upon dissection in the pathology 
suite, samples were cut into approximately 1g pieces and placed into pre-labed cyrovials 
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supplied in the sample kits. Samples were immediately frozen in liquid nitrogen vapor faze in 
charged vapor-shippers located at each site. An H&E slide was cut from the adjacent face of 
each tissue sample and sent to GCI along with the frozen tissue samples. Upon receipt at GCI, 
the samples were qualified by pathologist review of the H&E slide, and all samples were stored 
in Liquid N2 vapor freezers until requested for research. All clinical data, capture on Case 
Report Forms, was double-data entered in to a clinical database. 
 
DNA extraction, whole genome sequencing, and analysis 
DNA was extracted from colorectal carcinoma tumors and adjacent non-affected tissues 
and whole genome sequencing was performed as described previously [10]. Initial alignments to 
the human reference genome were performed as described [10]. All unaligned sequencing reads 
were (1) analyzed on PathSeq and (2) aligned to the complete set of fully sequenced bacterial 
and archaeal genomes (ftp://ftp.ncbi.nih.gov/genomes/Bacteria, downloaded 2010-10-07) by 
MegaBlast (Blast Tools version 2.2.23, word size 16, match reward 1, mismatch reward -2, gap 
open reward -5, gap extension reward -2). The top 30 sequence matches with >90% sequence 
identity and >90% query coverage were reported for each read (i.e. query). Classifications were 
performed at the domain, then phylum, then genus, then species level requiring unique 
alignments (i.e. reads with equivalent E-values to multiple taxa were removed from analysis). At 
the species level, relative abundance (RA) for each organism was calculated as follows: RA = (# 
unique alignment positions in genome * 1,000,000) / (# total alignable reads * genome size). The 
RA values were then per-sample normalized such that the total relative abundance for each 
sample sums to one. The resulting normalized RA matrix was analyzed on LEfSe [12]. 
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Amplification and 454 sequencing of 16S gene  
The 16S gene dataset consists of 454 FLX Titanium sequences spanning the V3 to V5 
variable regions obtained for 190 samples (95 pairs). Detailed protocols used for 16S 
amplification and sequencing are available on the HMP Data Analysis and Coordination Center 
website (http://www.hmpdacc.org/tools_protocols/tools_protocols.php). In brief, genomic DNA 
was subjected to 16S amplifications using primers designed incorporating the FLX Titanium 
adapters and a sample barcode sequence, allowing directional sequencing covering variable 
regions V5 to partial V3 (Primers: 357F 5'-CCTACGGGAGGCAGCAG-3' and 926R 5' 
CCGTCAATTCMTTTRAGT-3'). Polymerase chain reaction (PCR) mixtures (25µl) contained 
10ng of template, 1x Easy A reaction buffer (Stratagene, La Jolla, CA), 200mM of each dNTP 
(Stratagene), 200nM of each primer, and 1.25U Easy A cloning enzyme (Stratagene). The 
cycling conditions for the V3-V5 consisted of an initial denaturation of 95°C for 2 min, followed 
by 25 cycles of denaturation at 95°C for 40 sec, annealing at 50°C for 30 sec, extension at 72°C 
for 5 min and a final extension at 72°C for 7 min. Amplicons were confirmed on 1.2% Flash 
Gels (Lonza, Rockland, ME) and purified with AMPure XP DNA purification beads (Beckman 
Coulter, Danvers, MA) according to the manufacturer and eluted in 25 µL of 1X low TE buffer 
(pH 8.0). Amplicons were quantified on Agilent Bioanalyzer 2100 DNA 1000 chips (Agilent 
Technologies, Santa Clara, CA) and pooled in equimolar concentration. Emulsion PCR and 
sequencing were performed according to the manufacturer’s specifications. 
 
Processing of 16S sequence data 
Resulting sequences were processed using a data curation pipeline implemented in 
mother [22], complimented by abundantOTU [23], and custom PERL scripts.  Sequences were 
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removed from the analysis if they were <200 nt or >600 nt, had a read quality score <25, 
contained ambiguous characters, had a non-exact barcode match, or did show more than four 
mismatches to the reverse primer sequences (926R). Remaining sequences were assigned to 
samples based on barcode matches, after which barcode and primer sequences were trimmed and 
reads were oriented such that all sequences begin with the 5’ end according to standard sense 
strand conventions. All sequences were aligned using a NAST-based sequence aligner to a 
custom reference based on the SILVA alignment [22,24]. Chimeric sequences were identified 
using the mothur implementation of the ChimeraSlayer algorithm [25]. Quality filtered and 
chimera-free sequences were clustered into Operational Taxonomic Units 
(OTU's) using abundantOTU [23]. Representative sequences per OTU were classified with the 
MSU RDP classifier v2.2 [26], maintained at the Ribosomal Database Project (RDP 10 database, 
version 6). 
 
Quantitative PCR analysis 
Quantitative real-time PCR was performed as described [27] using pan-Fusobacterium 
probe-primer sets as described [27]. Fusobacterium quantitation was measured relative to human 
endogenous 18S (Applied Biosystems TaqMan® Ribosomal RNA Control Reagents, 
Hs99999901_s1 (part number 4331182)). 
 
Microbial FISH analysis 
Frozen sections were fixed in Carnoy’s solution overnight and embedded in paraffin, and 5 mm 
thick sections prepared and hybridized as previously described [15]. The sequences of the 
following FISH probes were obtained from probeBase (http://www.microbial-ecology. 
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net/probebase/) [14]: the ‘‘universal’’ bacterial probe-EUB338 (pB-00159), Fusobacterium 
targeted probe (pB-00782). Slides were imaged on an Olympus B40 microscope, digitally 
photographed using IP Lab. Three random fields per sample were chosen by an obsever blinded 
to tumor/normal status, using selection criteria of mucosal tissue depth and a minimum of 5 
bacteria visualized by the EUB338 probe per field. Composite z-stacks were assembled in IP Lab 
and composite photomicrographs were assembled in Adobe Photoshop. 
 
Data access 
The 16S sequence data from this study have been submitted to the NCBI Sequence Read 
Archive (http://www.ncbi.nlm.nih.gov/Traces/ sra/sra.cgi) under accession number SRP000383. 
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Fusobacterium nucleatum potentiates intestinal tumorigenesis 
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Abstract 
Deep-sequencing metagenomic analyses have revealed that Fusobacterium spp. are 
associated with human colorectal carcinoma. Here we show that in the ApcMin/+ mouse model of 
intestinal tumorigenesis, Fusobacterium nucleatum increases tumor multiplicity, selectively 
recruits tumor-infiltrating myeloid cells, and is associated with a pro-inflammatory expression 
signature that is shared with human fusobacteria-positive colorectal carcinomas. However, in 
contrast with recent studies of other bacteria in colorectal carcinoma, F. nucleatum does not 
exacerbate colitis or colitis-associated colorectal carcinoma. We find that Fusobacterium spp. are 
enriched in human colonic adenomas relative to surrounding tissues and fusobacterial abundance 
is increased in stool samples from patients with colorectal adenomas and carcinomas, compared 
to healthy subjects. Collectively, these data support that fusobacteria may be involved in early 
stages of intestinal tumorigenesis and, through recruitment of tumor-infiltrating immune cells, 
may generate a pro-inflammatory tissue microenvironment conducive to colorectal neoplasia 
progression. 
 
 
Introduction 
There is accumulating evidence that members of the gut microbiota contribute to 
colorectal cancer, the second most incident cancer worldwide with over 1.2 million new cases 
per year [1]. The majority of studies have focused on a small subset of colorectal cancers, colitis-
associated colorectal cancers, and employed rodent pre-clinical models. Antibiotic-treatment or 
absence of the gut microbiota reduced tumor incidence in several mouse colitis-associated 
colorectal cancer models [2-4]. Recently, two bacterial pathogens have been identified that 
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promote colitis-associated colorectal cancer. Enterotoxigenic Bacteroides fragilis induces colitis 
and colonic tumors in ApcMin/+ mice by triggering a T helper type 17 (Th17) inflammatory 
response [5], while adherent-invasive Escherichia coli strain NC101 promotes colitis-associated 
colorectal cancer in monocolonized, azoxymethane-injected Il10-/- mice [6]. However, the 
majority of human colorectal cancers do not arise in the setting of inflammatory bowel disease. 
The gut microbiota may be a driver in colorectal cancers that are not associated with 
colitis. Metagenomic analyses using whole-genome sequencing [7], transcriptome sequencing 
[8], or bacterial 16S ribosomal RNA gene DNA sequencing [7,9] have shown enrichment of 
Fusobacterium species in colorectal cancers relative to adjacent normal tissue. However, to date 
it has been unclear whether these findings represent an indirect association, or whether 
Fusobacterium spp. functionally contributes to colorectal cancer (CRC) tumorigenesis [10]. 
Here, we analyze the impact of Fusobacterium nucleatum on colorectal cancer 
progression and on tumor inflammation in mouse models, and assess the association of F. 
nucleatum in stool and colonic tissue from patients with colorectal adenomas and 
adenocarcinomas. Our data are consistent with the possibility that F. nucleatum potentiates non-
colitis associated colorectal tumorigenesis. 
 
 
Results 
Fusobacterium nucleatum promotes intestinal tumorigenesis 
 The enrichment of Fusobacterium spp. in colorectal cancers observed in three 
independent human cohort studies [7-9] prompted us to examine whether Fusobacterium could 
accelerate tumorigenesis in mouse models.  We began with pilot experiments in mice which have 
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a propensity to develop intestinal tumors because of a T to A transversion of nucleotide 2549 in 
one copy of the tumor suppressor gene Apc (C57BL/6 ApcMin/+) or because of genetic defects 
resulting in chronic intestinal inflammation (BALB/c Il10-/- and BALB/c T-bet-/- X Rag2-/-). We 
introduced a human clinical isolate of Fusobacterium nucleatum, several human clinical isolates 
of Streptococcus species (S. anginosus [4 mice]; S. parasanguinis [4 mice]; and S. sanguinis [4 
mice]), or tryptic soy broth to ApcMin/+ mice and F. nucleatum or tryptic soy broth to IL10-/- and 
T-bet-/- X RAG2-/- mice starting at 6 weeks of age. Streptococci were used as control strains 
because of the longstanding association of streptococcal species with occult colonic 
malignancies [11]. 
 Introduction of F. nucleatum into ApcMin/+ mice was associated with an accelerated onset 
of colonic tumors. ApcMin/+ mice fed F. nucleatum developed a significantly higher number of 
colonic tumors at 3.5 months of age as compared to ApcMin/+ mice fed Streptococcus (Strep.) 
spp., or tryptic soy broth control (P < 0.001, P < 0.0001) (Fig. 3-1a-c). However, F. nucleatum 
did not induce colitis (Fig. 3-1a-c) in contrast with enterotoxigenic Bacteroides fragilis, which 
causes colitis and accelerates tumorigenesis in ApcMin/+ mice [5]. Also, F. nucleatum neither 
exacerbated intestinal inflammation nor accelerated tumorigenesis in the two mouse models of 
colitis-associated colorectal cancer, Il10-/- and T-bet-/- X Rag2-/-, examined (Fig. 3-1a). 
In addition to increased colonic tumor numbers, ApcMin/+ mice fed F. nucleatum had a 
higher count of small intestinal adenomas versus Strep. spp (P = 0.0002), or soy broth (P = 0.02) 
and small intestinal adenocarcinomas versus Strep. spp (P = .0017) or tryptic soy broth (P = 
.0082) (Fig. 3-1d, e). Consistent with prior findings in human colorectal carcinoma [7,8], F. 
nucleatum was culturable from ApcMin/+  tumors and enriched in tumor tissue relative to adjacent 
normal tissue in F. nucleatum fed ApcMin/+ mice as assayed by qPCR (Fig. 3-1f). Furthermore, F.  
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Figure 3-1.  Fusobacterium nucleatum promotes intestinal tumorigenesis and is enriched in tumor tissues of 
ApcMin/+ mice. (a) Gross colon tumor counts and histologic colitis scores from ApcMin/+, Il10-/-, and T-bet-/- X Rag2-/- 
mice fed F. nucleatum (F. nuc), Streptococcus spp., or soy broth control. Mice were started on the 8-week, daily 
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(Figure 3-1 Continued) feeding regimen at 6 weeks of age. (*** P < 0.0001, ** P < 0.001, * P < 0.01). (b) 
Representative images of gross colons (ruler numbers in cm) and (c) colonic histological analysis of ApcMin/+ mice 
(100 micrometer scale bar). (d) Histopathologic small intestinal adenoma and adenocarcinoma counts in ApcMin/+ 
mice. (e) Representative sections of rolled small intestines from ApcMin/+ mice (ruler numbers in cm). (f) 
Fusobacterium abundance in matched tumor (T) versus normal (N) tissues from colons of ApcMin/+ mice fed F. 
nucleatum measured by quantitative PCR. (g) Representative FISH images of tumor and matched normal tissue 
from an ApcMin/+ mouse fed F. nucleatum using a Fusobacterium 16S rDNA-directed probe (50 micrometer scale 
bar). 
____________________________________________________________________________ 
nucleatum had a broad distribution within tumor tissue when visualized with fluorescence in situ 
hybridization using a Fusobacterium 16S rRNA-directed probe (Fig. 3-1g). Together, these 
results indicate that F. nucleatum may accelerate tumorigenesis in the absence of colitis, or 
macroscopic inflammation, in ApcMin/+ mice. 
F. nucleatum selectively expands myeloid-derived immune cells 
 Immune cells and their effectors have been found to be key components of the tumor 
milieu that promote neoplastic progression [12]. This type of inflammation has been referred to 
as intrinsic inflammation, as it is intrinsic to the tumor, in contrast with the extrinsic 
inflammation of IBD and colitis-associated colorectal cancer [12]. To address whether F. 
nucleatum contributes to tumorigenesis by an intrinsic inflammatory mechanism, we 
characterized and quantified the tumor infiltrating immune cells from the intestinal tumors of 
ApcMin/+ mice that were fed F. nucleatum or Streptococcus sanguinis for 8 weeks, or were not fed 
bacteria over the same time frame. Small intestinal rather than colonic tumors were used, 
because controls did not develop sufficient numbers of colon tumors within the experimental 
timeframe. 
 We observed a striking increase in infiltrating cells of the myeloid lineage in the tumors 
from Fusobacterium-treated mice. CD11b+ myeloid cells (mean 3.4X higher in cell number, 
mean 4.0X higher in % population) and CD11c+MHC class II+ dendritic cells (DC) (mean 3.1X 
higher in cell number, mean 2.7X higher in % population) increased in the tumors of ApcMin/+  
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Figure 3-2. F. nucleatum selectively expands myeloid-derived immune cells, but not lymphoid immune cells in 
the intestinal tumor microenvironment. Flow cytometric analyses:  (a) Percentage of intratumoral myeloid cells 
(upper panel) and lymphoid cells (lower panel). CD11b+ myeloid cells, CD11c+MHCIIhi dendritic cells, Gr-1+ 
CD11b- granulocytic neutrophils, CD3+CD4+ T cells, or CD3+CD8+ T cells (y-axes) vs forward scatter (FSC). Mean 
percentages  ± s.e.m are shown within each plot. n= 6, 4, or 15 for not treated, S. sanguinis, or F. nucleatum, 
respectively. (b) Cell number/gram tumor for myeloid and lymphoid cells from the treatment groups. (c) Cell 
number/gram tumor for TAM (CD45+CD11b+F4/80+). (d) Left panel, cell number/gram tumor for MDSC 
(CD45+CD11b+Gr-1+).  Right upper panel, cell number/gram tumor of monocytic MDSC (CD45+CD11b+Gr-1int 
Ly6Chi) and lower panel, granulocytic MDSC (CD45+CD11b+Gr-1hiLy6Clow). (e) Left panel, cell number/gram 
tumor of classical myeloid DCs (CD45+CD11c+MHCIIhi CD11b+) and right panel, cell number/gram tumor of 
tolerogenic DCs (CD45+CD11c+MHCIIhiCD103+). Each symbol represents data from an individual mouse. P values 
are shown where significant. 
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mice fed invasive F. nucleatum as compared to controls (Fig. 3-2a, b). In contrast, numbers of 
intratumoral CD11b-Gr-1+ granulocytic neutrophils and T lymphocytes, CD3+CD4+ and 
CD3+CD8+ cells, in mice fed F. nucleatum were not significantly different from controls (Fig. 3-
2a, b). 
 Substantial experimental data from clinical and pre-clinical studies indicate that tumor-
associated macrophages (TAM) promote tumor progression and metastasis [13-15]. We further 
characterized the intratumoral myeloid populations and found an enrichment of TAMs  
(CD11b+F4/80+) in F. nucleatum fed mice as compared to controls (mean 4.1X increased cell 
number) (Fig. 3-2c).  Myeloid-derived suppressor cells (MDSCs) represent an additional 
population of tumor-permissive myeloid cells with potent immune suppressive activity [16-19]. 
MDSCs (CD11b+Gr-1+) were enriched (mean 4.9X increased cell number) in F. nucleatum fed 
mice vs controls. There are two principal MDSC subsets, monocytic and granulocytic, both of 
which increased in the tumors of F. nucleatum fed mice (monocytic MDSCs (CD11b+Gr-
1intLy6Chi), mean 9.1X and granulocytic MDSCs (CD11b+Gr-1hiLy6Clow), mean 11.6X increased 
cell number) compared to controls (Fig. 3-2d). 
 Within tumors, dendritic cells (DC) can either dampen or promote anti-tumor immunity 
[20]. The goal of several current tumor immunotherapy efforts is to re-program and activate DCs 
within tumors, as intratumoral DCs can assume tumor permissive phenotypes [21]. The intestine 
possesses a specific subset of tolerance promoting DCs.  These tolerogenic DCs express the cell 
surface integrin CD103 and promote the expansion of Foxp3+ regulatory T cells, a CD4+ T cell 
subset that suppresses cytotoxic and effector T cells and thus dampen anti-tumor immunity [22-
24]. Having identified an expansion of DCs in F. nucleatum fed mice, we further characterized 
the DC populations and found increases in classical myeloid DCs (CD11c+MHCII+CD11b+) and 
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CD103+ tolerogenic DCs (CD11c+MHCIIhiCD103+)  (mean 3.5X and mean 2.8X increased cell 
number, respectively) compared to controls. (Fig. 3-2e). To determine whether the changes in 
TAMs, MDSCs, and DCs were impacting specific subsets of CD4+ T cells implicated in colon 
tumorigenesis [5,25], we examined both intratumoral T-helper 17 (Th17) cells and CD4+ Foxp3+ 
regulatory T cells. While there was a trend towards an increase in Foxp3+ regulatory T cells 
(Treg) and Th17 cells in F. nucleatum fed mice, there was significant heterogeneity within this 
group, that did not correlate with intratumoral F. nucleatum abundance, and differences were not 
statistically significant (Supplementary Fig. 3-1). Additionally, there was no trend between 
Th17 and Treg cell numbers in the same individual mice. Collectively, these data support that F. 
nucleatum modulates the tumor immune microenvironment and results in expansion of selective 
myeloid-derived immune cell types that have been well-described to promote tumor progression 
[14,26,27]. 
A Fusobacterium-associated human colorectal cancer gene signature shared and validated 
in mice 
 Given our findings of F. nucleatum-induced myeloid-derived cell expansion in mouse 
intestinal tumors, we asked if there would also be a similar immunological profile in human 
Fusobacterium-associated colon tumor transcriptomic data. We utilized a data set of deep 
transcriptome sequencing (i.e. RNA-Seq) of 133 colon tumors generated by The Cancer Genome 
Atlas [28]. All non-human sequencing reads were applied to PathSeq, a computational tool that 
identifies and quantifies the abundance of all bacteria present in each tumor [29]. By calculating 
the Spearman’s rank correlation coefficient of the relative abundance of Fusobacterium spp. 
transcripts with host gene expression in this dataset, we identified a Fusobacterium-associated 
human CRC gene expression signature. We found a correlation of immune cell marker genes 
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associated with TAM (CD209, CD206/MRC1, IL-6, IL-8, and CXCL10), MDSC (CD33 and IL-
6), and DC (CD11c/ITGAX, CD209, TNF, CD80) with Fusobacterium abundance in human 
Fusobacterium-associated tumors by RNA-Seq, similar to our findings with Fusobacterium in 
mouse flow cytometry experiments (Fig. 3-3a). Analysis using the Ingenuity IPA gene ontology 
module revealed that the Fusobacterium-associated human CRC gene expression signature was 
highly enriched for the inflammatory response gene ontology category (corrected P < 1x10-33; 
Ingenuity analysis) as well as other categories also related to immune and inflammatory disease 
(Supplementary Table 3-1). To test the specificity of this correlation, we performed the same 
analysis with the other top-four highly abundant genera besides Fusobacterium (Bacteroides, 
Escherichia, Streptococcus, and Propionobacterium), but none of these other genera had 
enrichment for inflammation-related gene functions, nor did they have comparably high gene 
ontology enrichments in any other functional categories (Supplementary Fig. 3-2).  Relative 
abundance of Fusobacterium spp. transcripts are shown for each of the 133 TCGA colon tumors 
with scaled expression values for the top 50 ranked genes denoted as the row Z-score in a heat 
map (Fig. 3-3b). Many of the these top ranked genes, PTGS2 (COX-2), IL1β, IL6, IL8, and TNF 
(TNF- α), have not only been investigated in colorectal carcinogenesis but also are induced by 
Fusobacterium in co-culture with human and mouse cell lines in vitro [30-32]. 
 The expression signature was suggestive of a NF-κB-driven pro-inflammatory response 
[33]. As NF-κB has been identified as a central link between inflammation and cancer [34], we 
assessed whether there was a correlation between increased NF-κB activation and 
Fusobacterium abundance in human colorectal cancers.  We obtained freshly resected human 
colorectal cancer samples and generated nuclear extracts from these samples. After stratifying 
the samples by their abundance of Fusobacterium spp., we performed western blots on the  
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Figure 3-3. A Fusobacterium-associated human colorectal cancer gene signature shared and validated in 
mice. (a) Immune cell types enriched in Fusobacterium-associated mouse tumor are shown with the human marker 
gene utilized to determine their abundance in the TCGA CRC RNA-seq data set. Spearman’s rank correlation 
coefficient of the relative abundance of Fusobacterium spp. transcripts and P values are shown next to each marker 
gene. (b) Ingenuity Pathway Analysis Biological Function Gene Ontology categories that are enriched for 
Fusobacterium abundance-correlating gene sets are shown. (c) Relative abundance of Fusobacterium spp. 
transcripts are plotted for each of the 133 TCGA colon tumors (upper panel and lower panel x-axis) and scaled 
expression values for the top 50 ranked genes denoted as the row Z-score (y-axis) are shown in a heat map (lower 
panel) with a purple (low expression)–yellow (high expression) color scale. (d) Western blot of nuclear extracts 
from human colon cancer with a high or low Fusobacterium relative abundance (see Methods) using an anti-NF-kB 
p65 antibody and the nuclear marker lamin B1. (e) qPCR analysis of a selection of the top 50 ranked genes in (B) in 
colon and small intestinal tumors from F. nucleatum vs tryptic soy broth fed ApcMin/+ mice. Tumors from 6-9 mice 
per group were used. Means and s.e.m. are plotted. P values are shown where significant. 
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nuclear extracts from Fusobacterium high and low tumors to examine NF-κB activation.  NF-κB 
was indeed more activated  (increased nuclear translocation of the p65 NF-κB subunit) in tumors 
with a high vs low Fusobacterium abundance (Fig. 3-3c, upper panel). 
 We found that most of the human Fusobacterium-associated pro-inflammatory genes 
with mouse homologs including: Ptgs2 (COX-2 mouse homolog), Scyb1 (IL8 mouse homolog), 
Il6, Tnf (TNFa), and Mmp3 were also more highly expressed in both small intestinal and colonic 
tumors from mice that were treated with F. nucleatum vs tryptic soy broth (Fig. 3-3e). 
Fusobacteria are enriched in colonic adenomas and in stools samples from patients with 
adenomas and colorectal carcinomas 
 Colonic adenomas are neoplastic epithelial lesions that have the potential to become 
malignant and are believed to be the precursors of the majority of sporadic colorectal cancers. 
Given the enrichment of Fusobacterium spp. in colorectal tumor versus adjacent normal tissue, 
we examined if there would be a similar enrichment in adenomas, suggesting the involvement of 
Fusobacterium in neoplastic initiation or progression, prior to the establishment of carcinoma.  A 
few recent studies have performed case control studies of colorectal adenomas using 16S rRNA 
gene surveys with one noting fusobacterial enrichments in their patient cohort [35-38]. We 
measured Fusobacterium spp. abundance in paired adenoma tissue versus adjacent normal tissue 
from the same patient drawing samples from several geographic locations and registries: The 
Cooperative Human Tissue Network (Eastern, Southern, and Western divisions of the United 
States), Massachusetts General Hospital (Boston, MA), and University of Aberdeen School of 
Medicine (Aberdeen, United Kingdom). We found that Fusobacterium was detectable by qPCR 
in 48% of adenomas (n=29), and in those cases that were positive, Fusobacterium was enriched 
in adenomas relative to surrounding tissue (P < 0.004) (Fig. 3-4a and Supplementary Table 3- 
	   98 
 
Figure 3-4. Fusobacterium is enriched in adenoma versus adjacent normal tissue and detected at a higher 
abundance in stool from CRC and adenoma cases than from healthy controls. (a) Fusobacterium abundance for 
normal tissue (x-axis) vs adenoma (y-axis) is plotted. Samples with no difference in fusobacterial abundance 
between adenoma and normal within a single patient are plotted on the diagonal line. 29 matched adenoma normal 
tissues pairs were tested. Each symbol represents data from one patient (adenoma and normal tissue). (b) Fecal 
Fusobacterium abundance from healthy subjects (n=30), subjects with colorectal adenomas (n=29), and colorectal 
cancer (n = 27). 
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3). These data suggest that Fusobacterium begins to accumulate at early stages of colonic 
tumorigenesis in some groups of patients. 
 Next, we determined if Fusobacterium spp. are enriched exclusively in tumor and 
adenoma tissue, or whether fusobacteria have a higher overall abundance in the fecal microbiota 
of CRC patients relative to healthy controls in a case-control experiment. We compared the 
levels of Fusobacterium spp. to universal Eubacteria 16S by quantitative qPCR of stool. These 
subjects provided their stool samples to the Early Detection Research Network (EDRN) prior to 
bowel preparation and screening colonoscopy and had no prior history of colorectal cancer or 
gastrointestinal disease (Fig. 3-4b and Supplementary Table 3-4). We found that 
Fusobacterium spp. were enriched in CRC patients (P < 1x10-5). Because of the Fusobacterium 
enrichment in adenomas (Fig. 3-4a), we examined the Fusobacterium spp. abundance in stool 
from patients who provided stools to the EDRN and who were subsequently diagnosed with 
colonoscopy-confirmed colonic adenomas (Fig. 3-4b and Supplementary Table 3-4).  We 
found that Fusobacterium spp. were also enriched in subjects with adenomas as compared to 
healthy control individuals (P < 5x10-3). These results indicate that increased abundance of 
Fusobacterium species in the gut microbiota may be a general feature of colonic tumorigenesis. 
 
 
Discussion 
 Entry of microbes and microbial products into the evolving tumor microenvironment 
potentiates tumor growth by eliciting tumor-promoting immune cell responses [25,39]. Our 
results demonstrate that Fusobacterium spp., rare gut microbiome constituents in the healthy 
human population [40], are found at increased abundance in the stool of patients with adenomas 
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and colorectal cancer, and are enriched in adenomas and adenocarcinomas relative to non-
involved colonic tissues. Introduction of Fusobacterium nucleatum to ApcMin/+mice resulted in 
accelerated small intestinal and colonic tumorigenesis, infiltration of specific myeloid cell 
subsets into tumors, and an NF-κB pro-inflammatory signature. This pro-inflammatory signature 
was shared with human colorectal cancer tissue with a high Fusobacterium abundance. 
 In contrast to other bacterial-driven models of intestinal tumorigenesis [5,6], we have 
found a specific bacterial strain that accelerates intestinal tumorigenesis in the absence of colitis. 
While ApcMin/+ mice fed F. nucleatum exhibited enhanced intestinal tumorigenesis, neither Il10-/- 
nor T-bet-/- X Rag2-/- mouse models of colitis showed accelerated tumorigenesis or exacerbated 
colitis upon introduction of F. nucleatum. This may suggest that the tumorigenic effects of 
fusobacteria operate downstream of the loss of the tumor suppressor APC and the resulting 
intestinal dysplasia that occurs in ApcMin/+ mice. This is relevant to most cases of human CRC, as 
only 2% of CRC cases are linked to colitis, but greater than 80% of non-hypermutated CRC 
tumors bear APC mutations [28]. Our Fusobacterium findings are also relevant to adenomas 
because mutations in APC are among the earliest molecular alterations that occur in an 
epithelium as it transitions to become an adenoma [41]. Therefore, early tumor-initiating somatic 
mutations likely precede the tissue enrichment of Fusobacterium spp. These mutations may 
contribute to the development of epithelial barrier defects, featuring the loss of tight junctions, 
cell-to-cell contacts, epithelial polarity and the mucus layer [25]. Intestinal barrier defects at 
local sites of dysplasia may promote the infiltration of Fusobacterium spp., among other bacteria 
and microbial products, allowing fusobacteria to take up residence in the tumor environment.  
This may represent a crucial stage in colorectal neoplasia wherein myeloid cell-mediated 
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immune responses provide the driving force for inflammatory genotoxic and epigenetic changes 
that lead to cancer. 
 Although barrier defects expose the intestinal mucosa to the entire luminal microbial 
milieu, Fusobacterium spp. become the most highly enriched bacterium in colorectal tumors 
relative to adjacent tissue [7,8,10]. This enrichment may be attributable to the strong adhesive 
and invasive abilities of fusobacteria to epithelial cells [42,43]. The tumor enrichment of 
fusobacteria may also result from the growth advantage it provides to the tumor by eliciting pro-
tumorigenic responses from myeloid immune cells. Alternatively, fusobacterial metabolic 
specializations may endow it with a competitive advantage in the evolving tumor milieu. 
Fusobacterium nucleatum is an asaccharolytic bacterium so, unlike the Enterobacteriaceae, it 
will not compete for glucose, a preferred substrate for tumor metabolism [44].  Instead 
fusobacteria can utilize amino acids and peptides as nutrient sources in the tumor 
microenvironment. Products of amino acid metabolism generated by fusobacteria, including 
formyl-methionyl-leucyl-phenylalanine and short chain fatty acids, are myeloid cell 
chemoattractants, which may explain the intratumoral myeloid cell expansion we observed and 
interconnect tumor metabolism, bacterial metabolism, and immune cell function within the 
tumor microenvironment. 
 In addition, F. nucleatum strains, unlike many strict anaerobes of the intestinal lumen, 
possess a rudimentary electron transport chain, endowing them with a limited ability to respire 
oxygen [45]. Thus, F. nucleatum may be able to persist and slowly replicate in the hypoxic 
tumor microenvironment. Adhesive molecules that contribute to invasivity in F. nucleatum can 
promote bacterial aggregation and biofilm formation that also enhance oxygen tolerance [46]. 
Products of fusobacterial metabolism may make the tumor microenvironment more tumor-
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permissive over time by directly promoting tumor cell proliferation, blood vessel growth, or 
immune cell infiltration. 
 We have shown that, in both human and mouse intestinal tumors, the pro-inflammatory 
gene expression signature associated with Fusobacterium features the up-regulation of PTGS2 
(COX-2). Epidemiological and clinical data suggest that non-steroidal anti-inflammatory drugs 
(NSAIDs) may be effective as a primary and secondary preventative measure in colorectal 
neoplasia [47].  Our findings on Fusobacterium spp. and the intrinsic inflammation it elicits may 
further explain why anti-inflammatory strategies such as NSAIDs are an effective colorectal 
cancer prevention strategy. 
 If our results demonstrating that fusobacteria potentiate tumorigenesis can be extended to 
human CRC, then targeting Fusobacterium populations in the oral cavity where it is most 
abundant [48], or in the gastrointestinal tract may work to delay or prevent tumor progression in 
patients at increased risk for CRC. We show that Fusobacterium is absent, or present at low 
basal levels, in the stool of healthy individuals, but is significantly more abundant in patients 
with a colonoscopy-confirmed adenoma or CRC. These findings suggest a need for 
epidemiological studies to evaluate whether Fusobacterium abundance can be utilized as a 
prognostic or diagnostic factor in colorectal cancer. 
 
 
Materials and Methods 
Bacterial strains and culturing 
Fusobacterium nucleatum (EAVG_002; 7/1) [43] was a gift from the laboratory of Emma 
Allen-Vercoe (U. Guelph). Streptococcus species were isolated from freshly resected human 
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colon tissues and identified by a combination of Gram stain and morphology, catalase test, 
hemolysis on Difco™ Tryptic Soy Blood Agar Base No. 2 (BD, Sparks, MD) supplemented with 
5% defibrinated sheep blood (Northeast Laboratory, Waterville, ME), and Sanger sequencing on 
16S rDNA positions 27-1492. 
 Bacteria were stored at -80°C in autoclaved freezing media, consisting of 1% DMSO, 1% 
glycerol, and 12% w/v skim milk powder in distilled water. F. nucleatum strains were plated on 
Fastidious Anaerobe Agar (Neogen, Lansing, MI) supplemented with 5% defibrinated sheep 
blood (Northeast Laboratory, Waterville, ME) and grown overnight in Bacto™ Tryptic Soy 
Broth (BD, Sparks, MD) (TSB) supplemented with 5µg/mL hemin, 1µg/mL menadione (Sigma 
Aldrich, St. Louis, MO), at 37°C in an anaerobic cabinet. Streptococcus strains were plated on 
TSB with 1.5% w/v agar (Neogen, Lansing, MI) supplemented with 5% defibrinated sheep blood 
(Northeast Laboratory, Waterville, ME), and grown overnight in TSB at 37°C in 5% CO2. 
Colony forming units (CFU) were measured by serial dilution and plating. 
Mice 
 All mice were maintained in a specific pathogen free barrier facility at the Harvard 
School of Public Health (HSPH) and all experimentation was carried out in accordance with 
institutional guidelines. Female ApcMin/+ mice were ordered from Jackson Laboratory (Jackson 
strain C57BL/6J-ApcMin/J) and received by 5 weeks of age and ApcMin/+ were bred at HSPH. 
BALB/c Il-10-/- and T-bet-/- Rag2-/- mice were maintained and bred within the HSPH barrier 
facility. 
Bacterial feeding experiments were performed for a period of 8 weeks, beginning at 6 
weeks of age. Bacteria were fed to mice by pipette at 108 CFU per day, at a maximum volume of 
100µL. Sham treatment consisted of 100µL of TSB. 
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Histopathology 
 Colons and small intestines were prepared for histologic analysis and assessed for colitis 
as previously described [49]. Adenomas (polyps with low-grade or high-grade epithelial 
dysplasia but no invasion) and invasive adenocarcinomas were counted in colons and small 
intestines submitted in their entirety. 
Human specimen collection 
 Colonic adenocarcinoma samples: Patients were identified from upcoming operative 
cases by co-investigator T.C. in the Department of Surgery at Brigham and Women’s Hospital.  
Inclusion criteria were patients who had biopsy-confirmed colorectal cancer and were 
undergoing hemicolectomy. Exclusion criteria included a known synchronous cancer diagnosis 
or other cancer diagnosis within five (5) years of the operation. The attending surgeon is a study 
investigator and obtained written informed consent preoperatively.  Once the specimen was 
removed, a portion of the tumor was allocated to members of the study and the remainder 
submitted for standard processing by the Pathology Department. No antibiotics were given pre-
operatively. Written informed consent was obtained from all participants. 
Colonic adenoma samples: Patients were identified and samples were collected by co-
investigator P.L. (U. of Aberdeen), D.C. (Massachusetts General Hospital), or by the 
Cooperative Human Tissue Network (U. of Pennsylvania, U. of Virginia Health System, 
Vanderbilt U. Medical Center). Written informed consent was obtained from all participants. 
 Stool samples: Samples were collected by the National Cancer Institute Early Detection 
Research Network. Written informed consent was obtained from each study participant. Colonic 
adenocarcinoma was confirmed by biopsy; colonic adenoma was confirmed by colonoscopy. All 
samples were collected pre-operatively. The samples were collected by subjects in their homes 
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using a “hat” or specimen collection container that fit under a toilet seat, then stool was packed 
into glass vials and placed on ice packs until shipped overnight and then stored at -80°C. 
DNA preparation and bacterial quantification by qPCR 
 Human and mouse tissues or stools (20-100mg) were digested overnight in 0.7mL 
molecular grade lysis buffer (100mM TrisHCl pH 8.5, 5mM EDTA pH 8.0, 0.2% SDS, 200mM 
NaCl, 1 mg/ml proteinase K) at 55°C with rotation. The samples were centrifuged at 20,000xg 
for 5min then the liquid portion was moved to equal volume isopropanol. The precipitated DNA 
was recovered and resuspended in 0.4mL TE buffer. An equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added, mixed by inversion, centrifuged at 
20,000xg  for 5min, then the aqueous phase was transferred to a fresh tube. If aqueous phase was 
milky, the phenol:chloroform:isoamyl alcohol step was repeated. 0.1 volume of 3M sodium 
acetate pH 5.2 and 2 volumes of 100% ethanol was added, incubated at -20C for 1hr, and 
centrifuged at 20,000xg for 15min. The pellet was washed 2 times by adding 0.5mL of 70% 
ethanol, centrifuging at 20,000xg for 7min, and discarding supernatant. The DNA pellet was 
resuspended in molecular grade water. For stool samples, an extra purification step was 
performed at this stage using the QIAquick Gel Extraction Kit (QIAGEN). 
 8ng of DNA was used in each 20µL KAPA SYBR® FAST qPCR (Kapa Biosystems, 
Woburn, MA) reaction, performed in triplicate, and analyzed on the Stratagene Mx3005P 
(Agilent Technologies, Santa Clara, CA). The following primer sets were used: Fusobacterium 
spp. (Fwd 5’-GGATTTATTGGGCGTAAAGC-3’; Rev 5’-
GGCATTCCTACAAATATCTACGAA-3’) [50], and universal Eubacteria 16S (Fwd 5’-
GGTGAATACGTTCCCGG-3’; Rev 5’-TACGGCTACCTTGTTACGACTT-3’). Relative 
abundance was calculated by the ΔCT method. 
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RNA preparation and gene expression by qPCR 
 Total RNA was extracted using the RNeasy® kit (QIAGEN), DNase treated with the 
DNA-free™ kit (Ambion), and cDNA was generated using the iScript™ cDNA Synthesis kit 
(Bio-Rad). All primers were ordered from Sigma Aldrich. Relative gene expression was 
calculated using the ΔΔCT method. Primers were designed using MGH primerbank: 
pga.mgh.harvard.edu/primerbank/ 
Microbial FISH analysis 
 Microbial FISH was performed as described previously [7]. 
RNA-Seq processing and analysis 
 All primary sequence data on colonic adenoma (COAD) samples (https://tcga-
data.nci.nih.gov/docs/publications/coadread_2012/) were downloaded from The Cancer Genome 
Atlas via dbGAP and the Data Coordinating Center (http://cancergenome.nih.gov/). At the time 
of analysis, 133 complete COAD RNA-Seq datasets were available. All datasets were analyzed 
on PathSeq [29] to calculate microbial relative abundance at the genus level. Relative abundance 
was defined as the number of uniquely-mapped microbial reads to a given genus, normalized for 
the total number of uniquely-mapped microbial reads per sample. Host gene expression was 
calculated using RPKM as described previously [28]. The Spearman’s rank correlation 
coefficient was calculated for each genus-host gene pairing. 
Detection of NF-κB activation 
 Fresh or fresh-frozen colon tumor tissue (20-80mg per sample) was processed for nuclear 
protein isolation with the NE-PER® Nuclear and Cytoplasmic Reagents Kit (Thermo Scientific, 
Rockford, IL). Protein lysates were resolved using SDS-PAGE and transferred to PVDF 
membrane using a Bio-Rad wet transfer apparatus. Blots were probed with antibodies directed 
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against p65 and lamin B1 (Cell Signaling Technology, Danvers, MA). Samples were stratified as 
Fusobacterium-high (qPCR Fusobacterium abundance greater than 40.0 [calculated as 1.8^(-
CT<Fusobacterium> - CT<Eubacteria>)*1000], or 16S sequencing Fusobacterium abundance 
greater than 0.25 [calculated as described previously [7]]) or Fusobacterium-low (qPCR 
Fusobacterium abundance less than 1.0, or 16S sequencing Fusobacterium abundance less than 
0.015). 
Isolation of intestinal tumor infiltrating cells 
 Small intestine was removed, cut longitudinally and washed with Ca+- and Mg+-free 
Dulbecco’s phosphate buffered saline (DPBS). Tumor nodules were dissected away from normal 
tissue, weighed, and then finely minced and incubated in Ca+- and Mg+-free Hank’s balanced salt 
solution (HBSS) with 0.1 mg/ml collagenase D (Roche) and 50 U/ml DNase I (Roche) for 30 
min at 37°C on a shaking platform. The solution containing digested tumors was filtered through 
a 70 µm cell strainer and centrifuged at 400 X g for 10 min. Isolated tumor infiltrating cells were 
resuspended in cell staining solution (PBS with 2% FCS) for flow cytometry analysis. 
Flow cytometry 
 For cell surface staining, cells were incubated with Fc blocking antibody (BioLegend) for 
15 min, and stained with fluorochrome-conjugated monoclonal antibodies of cell surface 
markers. Following antibodies were used and purchased from BioLegend or eBioscience: CD45 
(clone 30-F11), CD11b (clone M1/70), Gr-1 (clone RB6-8C5), CD11c (clone N418), MHC class 
II (clone M5/114.15.2), CD3ε (clone 145-2C11), CD4 (clone RM4.5), CD8α (clone 53-6.7), 
F4/80 (clone BM8), Ly6C (cloneHK1.4), CD103 (clone 2E7), and CD16/CD32 (clone 
CD16/CD32). For intracellular cytokine or Foxp3 staining, cells were stimulated for 4 h in RPMI 
complete medium with 50 ng/mL phorbol 12-myristate 13-acetate (PMA)(Sigma) and 500 
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ng/mL ionomycin (Sigma) in the presence of 5ug/mL Brefeldin A (BioLegend). Then, cells were 
stained with cell surface markers, fixed with Fix/Perm buffer (BioLegend), permeabilized with 
Perm buffer (BioLegend) according to the manufacturer’s recommendations and stained with 
anti-IL-17A (clone TC11-18H10.1, BioLegend) or anti-Foxp3 (clone FJK-16s, eBioscience) 
antibodies. Cells were stained in parallel with the respective control isotype antibodies. Stained 
cells were acquired using BD LSRII flow cytometry (BD Biosciences) and analyzed with 
FlowJo9 software (Tree Star). 
Statistical analysis 
 Generally, data is displayed in dot-plot format, with the center-line indicating the mean 
and the standard error of the mean represented by the error bars. All two-group comparisons 
were performed using the non-parametric Mann-Whitney U test, with the exception of Fig. 3-4a 
for which the non-parametric Wilcoxon matched-pairs signed rank test was performed. For 
RNA-Seq data, genus relative abundance was correlated to host gene expression using the 
Spearman’s rank correlation coefficient, and corrected P-values were obtained by correcting for 
multiple hypothesis testing using the False Discovery Rate method. Statistical analysis for 
Supplementary Table 3-2 was performed using the Fisher’s exact test. 
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CONCLUSION 
 
Perspectives on the Study of the Microbiota in Colorectal Cancer 
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 This thesis describes the composition of the colorectal tumor microbiome and explores 
the functional consequences of some of its constituents to tumorigenesis. First, we describe the 
development of new computational tools that were used in this analysis. PathSeq builds on the 
conceptual framework of computational subtraction, and for the first time, makes it technically 
feasible to analyze human whole-genome sequence datasets for the purpose of pathogen 
discovery. Second, we make use of whole-genome sequencing using PathSeq to perform the first 
large-scale study of the colorectal cancer microbiome. In performing this analysis, we identified 
a striking enrichment of the Fusobacterium genus in tumors. Although Fusobacterium is a rare 
gut constituent in healthy individuals, almost every colon tumor sequenced was positive for 
Fusobacterium. We then introduced an invasive human gut isolate of Fusobacterium nucleatum 
into ApcMin/+ mice and observed accelerated intestinal tumorigenesis as well as a tumor-
infiltrating myeloid cell inflammatory signature. 
 The value of these findings remains to be determined. An inherent limitation of any 
microbiome study that compares the composition of healthy versus diseased tissues or subjects is 
that the conclusions are correlative; such studies cannot address causation. A long-term 
prospective cohort study can be more informative than a case-control study because it allows for 
the identification of a particular shift in microbial composition at the time of disease onset. 
However, such a study design is significantly more complex, and it still cannot reveal whether 
the shift in microbial composition has a causal component or is merely a consequence of 
the disease state. An experimental animal-based study such as the one we have performed does 
address causation, however there are significant limitations in extrapolating results from animal 
studies to human disease. Therefore, taking the case of Helicobacter pylori and gastric cancer as 
an example, to assess whether Fusobacterium species can have a causal role in human colorectal 
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cancer we must combine results from epidemiological and case-control studies with mechanistic 
animal-based studies and build evidence in a cumulative fashion. 
 If Fusobacterium species do contribute to human colorectal tumorigenesis then this could 
have significant clinical implications. An exciting aspect of understanding the role of the 
microbiota in disease is that the microbiome, unlike the human genome, is extremely malleable. 
For example, the development and application of narrow-spectrum antibiotics that target the 
Fusobacteria may prevent or delay the onset of colon cancer in patients that are at high risk of 
developing the disease. Furthermore, although this route will require significantly more 
investigation, it is possible that altering the composition of the microbiota with the use specific 
probiotic formulations and even fecal transplants could deplete Fusobacterium species from the 
gut microbiota. 
 The enrichment of Fusobacterium species in colorectal tumors, regardless of its 
functional contribution to tumorigenesis, may serve as a clinically relevant biomarker. We have 
demonstrated that Fusobacterium spp. can be detected higher levels in stool from patients with 
colorectal carcinoma, and also in patients with pre-malignant polyps, relative to healthy control 
individuals. Therefore, such an assay may be of use as a non-invasive clinical diagnostic that 
could lead to the early detection of disease in some patients. 
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Supplementary Figure 1-1. Generation of artificial shotgun sequencing reads. (a) 20 million reads were 
generated from a human transcriptome database by randomly selecting 100-mer sequences. (b) A set of twelve virus 
genomes were selected. For each genome, substitutional mutations were introduced at twelve distinct mutation rates, 
and for each of these mutated genomes 100-mer sequences were chosen at random to produce the read set. 
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Supplementary Figure 1-2. Applying a sequencing error distribution model to artificially generated reads. (a) 
Average quality score plot for a typical set of reads generated by the Illumina GAII Sequencer. The Q-value is 
defined as Q=-10*log10(p/(1-p)), where p is the probability that the corresponding base call is incorrect. (b) The 
error distribution was applied to the complete set of reads generated as shown in Supplementary Figure 1. The plot 
shows the proportion of the read set containing a substituted base at the indicated position. (c) The proportion of the 
read set is shown as a function of the number of sequencing errors per read. 
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Supplementary Figure 1-3. Identification of virus-derived reads by sequence similarity. (a) Reads were 
generated as indicated in Supplementary Figure 1-1b. The proportion of reads identified as a virus sequence 
(MegaBlast alignment, E-value < 10e-10) is shown as a function of the substitutional mutation rate of the mutated 
genome. (b) Independent assemblies were performed on all reads from each of the 144 genomes. The proportion of 
reads incorporated into contigs that were identified as a virus sequence (MegaBlast alignment, E-value < 10e-10) is 
shown. 
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Supplementary Figure 1-4. Probability of contig formation for sequences randomly generated from a genome 
of varying size. This figure shows the probability of forming contigs from a set of simulated, virus-derived reads. 
Reads were generated by selecting random 100-mers from a series of genomes ranging in size from 100bp to 
20,000bp, producing between 2 and 20 reads per genome. The heatmap indicates the frequency among 11 replicates 
with which a contig of at least 175bp was formed from these reads by de novo assembly. 
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Supplementary	  Figure	  2-­‐1.	  Phylum-­‐level	  microbial	  classifications	  of	  whole-­‐genome	  sequencing	  on	  
nine	  colon	  tumor	  and	  normal	  tissue	  pairs.	  Phylum-­‐level	  classification	  demonstrates	  that	  most	  specimens	  are	  dominated	  by	  the	  Bacteroidetes	  and	  Proteobacteria,	  collectively	  making	  up	  greater	  than	  80%	  of	  all	  phyla	  in	  some	  samples.	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Supplementary	  Figure	  2-­‐2.	  Whole	  genome	  sequencing	  identifies	  the	  Streptococcaceae	  family	  as	  
significantly	  enriched	  in	  colon	  tumors.	  The	  relative	  abundance	  of	  sequences	  classified	  in	  the	  
Streptococcaceae	  family	  is	  shown	  for	  nine	  colon	  tumor/normal	  paired	  samples	  by	  whole-­‐genome	  sequencing.	  The	  Streptococcaceae	  family	  was	  found	  to	  be	  significantly	  enriched	  in	  tumors.	  Compare	  with	  Fig.	  2-­‐1d	  which	  shows	  the	  relative	  abundance	  of	  Fusobacterium	  sequences	  in	  the	  same	  set	  of	  samples.	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Supplementary	  Figure	  2-­‐3.	  Phylum-­‐level	  relative	  abundance	  of	  the	  microbiota	  by	  16S	  rDNA	  
sequencing	  on	  95	  colon	  tumor	  and	  normal	  tissue	  pairs.	  Median	  relative	  abundance	  measurements	  at	  the	  phylum	  level	  are	  reported	  across	  all	  95	  tumor	  and	  normal	  sample	  pairs,	  demonstrating	  a	  relative	  depletion	  of	  the	  Bacteroidetes	  and	  Firmicutes	  in	  the	  tumor.	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Supplementary	  Figure	  2-­‐4.	  Microbial	  diversity	  in	  the	  colon	  cancer	  microbiome.	  Comparison	  of	  the	  microbial	  diversity	  in	  tumor	  and	  normal	  tissues	  by	  rarefaction	  analysis	  on	  the	  OTUs	  detected	  by	  16S	  rDNA	  sequencing	  (a)	  across	  all	  samples	  and	  (b)	  on	  a	  sample-­‐by	  sample	  basis	  by	  using	  the	  QIIME	  package	  chao1	  metric	  (see	  Materials	  and	  Methods),	  a	  species	  richness	  indicator.	  (c)	  Correlation	  of	  species	  richness	  with	  tumor	  stage	  by	  the	  chao1	  metric	  (red:	  normal;	  blue:	  stage	  I;	  orange:	  stage	  II;	  green:	  stage	  III;	  purple:	  stage	  IV)	  demonstrates	  that	  higher	  stage	  tumors	  exhibit	  greater	  species	  richness.	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Supplementary	  Figure	  2-­‐5.	  Fusobacterium	  load	  correlates	  with	  geography.	  16S	  rDNA	  sequencing	  shows	  an	  increased	  mean	  relative	  abundance	  of	  Fusobacterium	  OTUs	  in	  tumors	  from	  patients	  in	  Barcelona,	  Spain	  versus	  GCI	  samples,	  which	  are	  a	  composite	  collection	  consisting	  of	  samples	  from	  the	  United	  States	  and	  Vietnam.	  P-­‐value	  calculated	  using	  a	  two-­‐sample	  t-­‐test.	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Supplementary	  Figure	  2-­‐6.	  Validation	  of	  the	  tumor-­‐enrichment	  of	  Fusobacterium	  by	  quantitative	  PCR.	  
(a)	  Absolute	  quantification	  of	  Fusbacterium	  DNA	  relative	  to	  a	  standard	  curve	  produced	  using	  Fusobacterium	  
nucleatum	  genomic	  DNA	  and	  quantitative	  PCR	  probe	  specific	  to	  the	  Fusobacterium	  genus.	  19	  data	  points	  are	  beyond	  the	  y-­‐axis	  limits	  but	  are	  reflected	  in	  the	  mean	  and	  standard	  error	  of	  the	  mean	  indicated	  on	  the	  plot.	  P-­‐value	  calculated	  by	  a	  Wilcoxon	  matched-­‐pairs	  signed	  rank	  test	  (non-­‐parametric).	  (b)	  Quantification	  of	  Fusobacterium	  in	  tumor	  relative	  to	  normal	  by	  use	  of	  the	  ΔΔCt	  method	  quantitated	  against	  a	  probe	  targeting	  human	  endogenous	  18S.	  
	   128 
	  
Supplementary	  Figure	  2-­‐7.	  Fluorescence	  in	  situ	  hybridization	  (FISH)	  detects	  enrichment	  of	  
fusobacteria	  in	  colorectal	  tumors.	  (a)	  Total	  bacterial	  count	  data	  using	  an	  Oregon-­‐Green	  488-­‐conjugated	  ‘‘universal	  bacterial’’	  16S	  rDNA-­‐directed	  oligonucleotide	  probe	  (EUB338)	  is	  shown	  for	  3	  random	  40X	  fields	  chosen	  for	  scoring	  by	  an	  observer	  blinded	  to	  tumor/normal	  status.	  Total	  bacterial	  counts	  were	  not	  enriched	  in	  either	  tumor	  or	  normals	  (P	  =	  0.0517).	  This	  corresponds	  to	  Fig.	  3B,	  which	  shows	  Fusobacterium	  counts.	  FISH	  was	  also	  performed	  on	  formalin-­‐fixed,	  paraffin-­‐embedded	  (FFPE)	  colorectal	  tumor	  and	  normal	  tissues	  using	  5	  random	  40X	  fields	  with	  the	  Cy3-­‐	  conjugated	  Fusobacterium-­‐directed	  (FUSO)	  probe	  (enriched	  in	  tumor;	  p	  =	  0.014).	  Epithelial	  cell	  nuclei	  were	  stained	  with	  DAPI	  (b)	  and	  the	  ‘‘universal	  bacterial’’	  EUB	  probe	  (no	  enrichment;	  p	  =	  0.1024)	  (c).	  All	  p-­‐values	  were	  calculated	  using	  a	  Wilcoxon	  matched-­‐pairs	  signed	  rank	  test	  (non-­‐parametric).	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Supplementary	  Figure	  2-­‐8.	  Quantitation	  of	  Fusobacterium	  across	  analytic	  methods.	  A	  comparison	  of	  
Fusobacterium	  quantitation	  is	  shown	  for	  the	  first	  9	  sample	  pairs	  by	  whole-­‐genome	  sequencing	  relative	  abundance,	  16S	  rDNA	  sequencing	  relative	  abundance,	  absolute	  Fusobacterium	  DNA	  levels	  by	  quantitative	  PCR,	  and	  Fusobacterium	  cell	  counts	  by	  fluorescence	  in	  situ	  hybridization.	  “N.D.”	  indicates	  “not	  determined.”	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Supplementary	  Figure	  2-­‐9.	  Relative	  abundance	  measurements	  for	  Fusobacterium	  OTUs	  in	  human	  
colon	  cancer	  tissues.	  The	  relative	  abundance	  of	  each	  of	  the	  five	  major	  OTUs	  in	  colon	  tumors	  (left	  panel)	  and	  normal	  tissue	  (right	  panel)	  is	  represented	  on	  a	  per-­‐patient	  basis	  (each	  row	  represents	  a	  different	  individual).	  The	  percent	  relative	  abundance	  is	  denoted	  by	  a	  color	  gradient	  indicating	  relatively	  low	  abundance	  in	  blue	  (0-­‐10%),	  very	  high	  abundance	  in	  dark	  red	  (>80%),	  and	  a	  range	  of	  other	  colors	  to	  specify	  intermediate	  abundance.	  The	  percentage	  signifies	  the	  abundance	  of	  the	  indicated	  OTU	  relative	  to	  all	  other	  phylotypes	  in	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Supplementary Figure 3-1. F. nucleatum does not affect intratumoral Th17 nor Foxp3+ Treg cell numbers. 
Flow cytometric analyses: Cell number/gram tumor of (a) CD3+CD4+ IL-17+ T cells and (b) CD3+CD4+ Foxp3+ T 
cells. Each symbol represents data from an individual mouse.  
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Supplementary Figure 3-2. Human colon tumor RNA-Seq analysis shows enrichment for inflammatory 
functions in genes correlated with Fusobacterium abundance but not the abundance of other genera. 
Spearman’s rank correlations of genus-level microbial relative abundance with host gene expression was used to 
weight Gene Ontology enrichment using Ingenuity Pathway Analysis software for the top 5 most abundant genera. 
Gene-set intersect indicates the number of genes that are shared in the enriched gene sets between Fusobacterium 
and each of the other genera. 	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Supplementary Table 1-1. Bacterial genomes used to construct an artificial sequence dataset to test the 
metagenomics module of PathSeq. Shown is the set of bacterial genomes that were each used to create a set of 
10,000 random 100-mers. The species were chosen to represent both evolutionary relatedness and divergence to test 
the ability of the metagenomics module to properly assess the microbial representation of a mixed sample. 
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Supplementary Table 1-2. Metagenomic analysis on a sequence dataset constructed from a set of twelve 
bacterial genomes. Shown is the number of reads that were identified as matching to the indicated bacterial genome 
(actual number of reads is 10,000 for each species). 
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Supplementary Table 1-3. PathSeq performance on artificially generated sequence data. Reads were generated 
by sampling random 100-mer sequences from a human transcriptome database, generating 20 million reads, or from 
a set of twelve virus genomes each substitutionally mutated at twelve distinct rates, generating 144,000 reads. The 
rows represent the number of reads remaining at each step in the PathSeq workflow. 
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Supplementary Table 1-4. PathSeq performance on artificially generated sequence data with introduced 
sequencing errors. Reads are the same as in Supplementary Table 1-3 except that “sequence errors” were 
introduced into the reads according to a sequencing error distribution model. 
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Supplementary	  Table	  2-­‐1.	  PathSeq	  run-­‐statistics	  and	  microbial	  classifications	  using	  colon	  cancer	  
human	  whole-­‐genome	  sequencing	  data.	  Shown	  is	  the	  total	  number	  of	  reads,	  total	  number	  of	  quality-­‐filtered	  (QF)	  reads,	  and	  reads	  identified	  as	  microbial	  sequences	  following	  PathSeq	  analysis	  (see	  Materials	  
and	  Methods)	  for	  each	  of	  the	  9	  colorectal	  tumor/normal	  pairs.	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Supplementary	  Table	  2-­‐2.	  Identification	  of	  viruses	  in	  colon	  cancer	  human	  whole-­‐genome	  sequencing	  
data	  by	  PathSeq	  analysis.	  Virus	  sequences	  were	  identified	  among	  the	  remaining	  non-­‐human	  reads	  following	  analysis	  with	  PathSeq.	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Supplementary	  Table	  2-­‐3.	  Quantitative	  PCR	  for	  Fusobacterium	  in	  colon	  cancer	  cell	  lines.	  Quantitative	  PCR	  was	  performed	  using	  a	  Fusobacterium-­‐directed	  probe	  compared	  against	  a	  human	  endogenous	  18S-­‐directed	  probe	  on	  both	  DNA	  and	  RNA	  extracted	  from	  each	  of	  the	  indicated	  colon	  cancer	  cell	  lines.	  The	  qPCR	  signal	  was	  strong	  for	  the	  endogenous	  control	  target	  but	  completely	  absent	  for	  the	  fusobacterial	  target.	  All	  experiments	  were	  performed	  in	  triplicate.	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Supplementary	  Table	  2-­‐4.	  Quantitative	  PCR	  for	  Fusobacterium	  in	  metastases	  from	  colorectal	  
carcinoma.	  Quantitative	  PCR	  using	  a	  probe	  targeting	  a	  region	  of	  16S	  rDNA	  conserved	  among	  fusobacteria	  (see	  Methods)	  shows	  that	  2	  of	  11	  colon	  metastases	  to	  the	  liver	  or	  lymph	  nodes	  have	  a	  positive	  signal.	  All	  positive	  results	  were	  positive	  in	  three	  replicates.	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Supplementary	  Table	  2-­‐5.	  Reference	  strain	  identification	  for	  Fusobacterium	  phylogenetic	  analysis.	  Abbreviated	  names	  used	  in	  the	  phylogenetic	  tree	  in	  Fig.	  2-­‐4a	  are	  specified	  using	  complete	  Greengenes	  strain	  names.	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Supplementary Table 3-1. Sample list of all colonic adenomas assessed for Fusobacterium abundance. 
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Supplementary Table 3-2. Fusobacterium is detected at a higher abundance in stool from CRC and adenoma 
cases than from healthy controls. 
 
 
  
 
 
